[{"text": "Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa\u00ae Gene Therapy in Combination with Tecentriq\u00ae to Treat Small Cell Lung Cancer PR Newswire Thu, Jan 23, 2025, 4:00 PM 8 min read In This Article: GNPX -7.84% Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis Acclaim-3 Study Has FDA Orphan Drug and Fast Track Designations AUSTIN, Texas , Jan. 23, 2025 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company's Acclaim-3 clinical study of Reqorsa \u00ae Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq \u00ae (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC). (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.) \"We are excited to begin the Phase 2 expansion portion of Acclaim-3, which will determine the 18-week Progression Free Survival (PFS) rate of REQORSA and Tecentriq combination maintenance therapy,\" said Mark Berger , MD, Chief Medical Officer at Genprex. \"ES-SCLC has a poor prognosis with a median PFS of 5.2 months. Those patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. We look forward to studying the combination of REQORSA and Tecentriq as we work to advance our innovative gene therapy.\" The Phase 2 expansion portion will enroll 50 patients at approximately 10 to 15 U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 interim analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. The Company expects to complete enrollment of the first 25 patients in the second half of 2025 for interim analysis. The combination of REQORSA and Tecentriq previously received the U.S. Food and Drug Administration's (FDA) Fast Track Designation for the treatment of the Acclaim-3 patient population, and the FDA has also granted Orphan Drug Designation to REQORSA for the treatment of SCLC. Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq. Story Continues Data presented at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from studies in humanized mouse models of SCLC that use human H841 SCLC cells have shown that the combination of REQORSA and Tecentriq provides significantly better control of tumor burden than either agent alone.\u00a0The data from these studies also suggest that a combination treatment of REQORSA and Tecentriq can promote a significantly increased tumor cell killing effect in SCLC xenografts compared to that of Tecentriq alone. About Acclaim-3 The Acclaim-3 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, Reqorsa \u00ae Gene Therapy, in combination with Genentech, Inc.'s Tecentriq \u00ae (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex \u00ae Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa \u00ae Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website , registering for Email Alerts and by following Genprex on Twitter , Facebook and LinkedIn . Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under \"Item 1A \u2013 Risk Factors\" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023 . Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications, such as REQORSA in combination with other therapies in SCLC; the timing and success of Genprex's clinical trials and regulatory approvals, including, but not limited to, the enrollment of the Phase 2 expansion portions of the Acclaim-3 trial; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations investors@genprex.com GNPX Media Contact Kalyn Dabbs media@genprex.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/genprex-announces-first-patient-dosed-in-phase-2-expansion-portion-of-acclaim-3-clinical-study-of-reqorsa-gene-therapy-in-combination-with-tecentriq-to-treat-small-cell-lung-cancer-302358445.html SOURCE Genprex, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2025-01-23T13:00:00+00:00", "sentiment": {"score": 0.12931053899228573, "confidence": 0.14962327480316162, "probabilities": {"positive": 0.14962327480316162, "negative": 0.020312735810875893, "neutral": 0.8300639390945435}}, "embedding": [-0.07732775807380676, 0.013835190795361996, -0.025068756192922592, -0.05549369752407074, -0.03669049218297005, 0.00355112855322659, -0.12032949924468994, 0.18608655035495758, 0.14945782721042633, 0.029755834490060806, -0.01354012731462717, 0.09420758485794067, 0.05587111413478851, 0.06196673959493637, -0.04496874660253525, 0.06467114388942719, 0.008974606171250343, 0.033802878111600876, -0.07981468737125397, 0.03947225958108902, 0.019135640934109688, -0.003662919159978628, 0.08862463384866714, 0.016896221786737442, 0.0852285772562027, -0.016487913206219673, -0.14941713213920593, 0.06315456330776215, -0.06044670194387436, 0.03426523506641388, 0.11612372100353241, 0.1968294233083725, -0.07860687375068665, -0.05122651904821396, 0.02101845294237137, 0.00996516551822424, -0.14944523572921753, 0.15691426396369934, -0.16148054599761963, -0.07264158129692078, 0.000753350555896759, 0.0650399848818779, -0.15179038047790527, 0.13266190886497498, 0.04495972767472267, -0.21054986119270325, -0.2613162398338318, 0.044244203716516495, -0.0011473451741039753, 0.1727280467748642, -0.044208161532878876, -0.09951215982437134, -0.06314627081155777, 0.18240776658058167, -0.003973496612161398, 0.07262252271175385, -0.13595685362815857, -0.054213352501392365, -0.0017908511217683554, -0.048692382872104645, -0.04460056126117706, -0.15531465411186218, -0.018661167472600937, -0.04586014524102211, 0.15364821255207062, 0.032236307859420776, 0.1014765053987503, -0.13609813153743744, -0.09699371457099915, 0.0021767541766166687, 0.025101983919739723, -0.006119665689766407, 0.017557423561811447, 0.21572674810886383, -0.06689693033695221, 0.1348709613084793, 0.16395586729049683, 0.06086864694952965, 0.037477534264326096, -0.025563592091202736, 0.01124099176377058, 0.0651550218462944, 0.014349355362355709, 0.021903373301029205, -0.015628814697265625, -0.04290902242064476, 0.003049675840884447, 0.1580335646867752, 0.07996220141649246, 0.012653479352593422, 0.06580214947462082, 0.09297637641429901, 0.010103365406394005, 0.06402229517698288, 0.040925394743680954, -0.004903661552816629, -0.11386796087026596, -0.018982242792844772, 0.0985962375998497, -0.09897071868181229, 0.07893864065408707, -0.1448594480752945, 0.009366056881844997, -0.07355297356843948, -0.08977057784795761, -0.07645496726036072, 0.002635002601891756, -0.024402780458331108, -0.03848192095756531, 0.033433426171541214, -0.027239179238677025, 0.023639705032110214, 0.17954325675964355, -0.05092943459749222, -0.09319472312927246, 0.3118559718132019, -0.09083910286426544, 0.04716332256793976, 0.24978995323181152, -0.08247961848974228, 0.053877003490924835, -0.022851422429084778, 0.020598143339157104, -0.07112280279397964, 0.12999826669692993, 0.10543201863765717, -0.027288267388939857, 1.3183327836209315e-32, -0.03323349356651306, -0.021707823500037193, 0.002188250422477722, 0.13902495801448822, 0.04341661557555199, -0.0065070223063230515, 0.13557153940200806, 0.0008827634155750275, -0.1463683843612671, -0.2317892611026764, -0.13389238715171814, 0.08831609785556793, -0.02998037450015545, 0.003039717674255371, -0.1125001609325409, -0.07843942940235138, -0.04006992280483246, 0.040936246514320374, -0.08694961667060852, -0.01583242230117321, -0.005601498298346996, 0.030753422528505325, 0.005246701650321484, -0.024772394448518753, 0.013979434967041016, -0.027315856888890266, -0.08525156229734421, 0.04316556453704834, -0.0018424522131681442, 0.03438891842961311, -0.03674207627773285, 0.124990314245224, -0.045796021819114685, -0.12607017159461975, -0.059097930788993835, -0.05921994894742966, -0.023984313011169434, -0.04968665540218353, 0.1122577041387558, 0.08296214044094086, -0.07478269189596176, 0.10568428039550781, -0.016549186781048775, -0.09576759487390518, -0.0032765972428023815, -0.24354970455169678, -0.05066266655921936, -0.025607768446207047, -0.028309954330325127, -0.008549254387617111, 0.07798565924167633, -0.07916015386581421, -0.08097247779369354, -0.010836966335773468, -0.09784582257270813, 0.02567838877439499, -0.1176365315914154, -0.020071009173989296, -0.017842911183834076, 0.049445658922195435, -0.0016229916363954544, 0.09790743887424469, 0.005814361851662397, 0.060450613498687744, -0.036776743829250336, 0.07092904299497604, -0.09461165964603424, -0.06496551632881165, -0.0329672135412693, 0.14398057758808136, 0.0616815984249115, -0.053398195654153824, 0.18116696178913116, -0.07849044352769852, 0.13665631413459778, -0.13399918377399445, 0.13528358936309814, 0.20466646552085876, -0.028100885450839996, 0.10030505061149597, -0.014671974815428257, 0.05358267202973366, -0.19258160889148712, 0.14563362300395966, 0.011128484271466732, -0.2076830416917801, 0.07105284184217453, 0.047500673681497574, -0.11816146969795227, -0.06163083761930466, 0.13588804006576538, -0.1053006649017334, -0.034017547965049744, 0.14394864439964294, 0.0698438510298729, -1.2234928708390324e-32, -0.014809567481279373, 0.054094016551971436, 0.1334969699382782, -0.04609312862157822, -0.04748237505555153, 0.08221520483493805, 0.011653924360871315, -0.05820988491177559, 0.06654977053403854, -0.19015565514564514, 0.07845138758420944, 0.08280852437019348, 0.009733195416629314, -0.011090334504842758, -0.15898743271827698, -0.015603018924593925, -0.014157947152853012, -0.096555694937706, -0.16862262785434723, 0.030791526660323143, 0.09440793842077255, 0.06299588829278946, -0.1055915355682373, 0.054971352219581604, -0.032233841717243195, -0.014599019661545753, 0.1620187908411026, 0.08972232788801193, -0.01831153966486454, -0.10929420590400696, -0.09652966260910034, -0.029119592159986496, -0.1736966073513031, 0.06089775264263153, 0.07666515558958054, -0.05920374020934105, 0.15377897024154663, -0.1364111751317978, -0.05330948531627655, -0.13727383315563202, 0.06061709299683571, 0.03000979870557785, -0.08133842051029205, 0.03061002865433693, -0.007106759585440159, 0.06641184538602829, 0.16270166635513306, -0.08132341504096985, 0.09824652969837189, 0.028004607185721397, -0.013629003427922726, 0.07780405879020691, -0.02055669203400612, 0.1215885579586029, 0.017214037477970123, -0.048590436577796936, -0.021172406151890755, -0.045206088572740555, -0.18375390768051147, 0.04470207914710045, 0.04687982425093651, 0.06834252923727036, -0.01797635294497013, -0.08928720653057098, 0.09732886403799057, 0.13792787492275238, 0.04519065469503403, 0.05749808996915817, 0.09805412590503693, -0.08146549761295319, -0.17079102993011475, -0.0028785988688468933, -0.049577049911022186, -0.14937381446361542, 0.01461494155228138, 0.08574840426445007, 0.0030186139047145844, -0.07882453501224518, -0.05705598369240761, -0.051893554627895355, -0.08776496350765228, -0.061454735696315765, -0.07940009236335754, -0.05345294997096062, 0.0783756673336029, 0.05942106992006302, 0.01780920848250389, 0.009439706802368164, 0.08054651319980621, 0.06200382113456726, -0.04984687641263008, -0.025599053129553795, -0.05064219608902931, 0.054217420518398285, 0.06265407800674438, -1.0073311784708494e-07, 0.05330260843038559, -0.03596048429608345, 0.012506050989031792, -0.07867010682821274, 0.10090827941894531, -0.07284839451313019, -0.03287004679441452, 0.06969942897558212, 0.061190906912088394, 0.17577096819877625, 0.07356219738721848, 0.143823504447937, -0.11447776854038239, -0.07919861376285553, -0.03299345076084137, 0.06636479496955872, -0.05685902386903763, -0.00677670631557703, 0.0039603449404239655, -0.018423402681946754, -0.17899049818515778, -0.033686209470033646, 0.01887226663529873, -0.045548226684331894, -0.05165261775255203, -0.06498925387859344, 0.06270632147789001, 0.050213806331157684, 0.0527397021651268, -0.09669093787670135, -0.11754349619150162, -0.08947260677814484, 0.0019635548815131187, 0.011731944046914577, -0.10391193628311157, -0.10823675245046616, 0.0949540063738823, 0.06356747448444366, 0.11910508573055267, 0.13463684916496277, 0.16585616767406464, 0.016301561146974564, 0.01369570940732956, 0.031683944165706635, -0.04513188451528549, -0.06314392387866974, -0.14977926015853882, -0.05998235195875168, -0.023775111883878708, -0.12357515096664429, -0.008518734015524387, -0.11826293915510178, -0.0069232964888215065, -0.14087936282157898, -0.06483124196529388, 0.11479631811380386, -0.08632740378379822, 0.007928770035505295, 0.0408845990896225, 0.023234495893120766, 0.014515724033117294, -0.04635211452841759, 0.044949259608983994, 0.02679220214486122], "changes": {"1wk": -12.056734830427319}}, {"text": "Genprex doses first subject in expansion part of lung cancer gene therapy trial The combination regimen will be assessed as a maintenance therapy to treat extensive stage small cell lung cancer patients. Credit: Jo Panuwat D/Shutterstock. \u00b7 Clinical Trials Arena \u00b7 Jo Panuwat D/Shutterstock. GlobalData Fri, Jan 24, 2025, 3:28 PM 2 min read In This Article: GNPX -7.84% Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene therapy (quaratusugene ozeplasmid) for extensive-stage small-cell lung cancer (ES-SCLC) patients. The trial will assess the gene therapy as a maintenance therapy, along with Genentech\u2019s Tecentriq (atezolizumab). This expansion cohort is set to recruit 50 subjects across ten to 15 sites in the US. Subjects will receive the combination regimen until they experience either disease progression or intolerable toxicity. Determining the 18-week progression-free survival rate from the commencement of maintenance therapy is the primary endpoint of this part of the trial. Subjects\u2019 survival will also be monitored, with an interim analysis scheduled after the 25th patient reaches 18 weeks of follow-up. Enrolment for this interim analysis is anticipated to conclude in the second half of this year. Genprex chief medical officer Mark Berger said: \u201cWe are excited to begin the Phase II expansion portion of Acclaim-3, which will determine the 18-week progression-free survival (PFS) rate of REQORSA and Tecentriq combination maintenance therapy. \u201cThose patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. We look forward to studying the combination of REQORSA and Tecentriq as we work to advance our innovative gene therapy.\u201d The US Food and Drug Administration (FDA) previously granted fast track status to the combination therapy for treating the Acclaim-3 subjects. The gene therapy has also been granted orphan drug designation to treat SCLC. In May 2024, the company enrolled and dosed the first subject in the Phase I/II trial to assess this combination therapy for ES-SCLC. \"Genprex doses first subject in expansion part of lung cancer gene therapy trial\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2025-01-24T12:28:49+00:00", "sentiment": {"score": 0.15508156456053257, "confidence": 0.16504190862178802, "probabilities": {"positive": 0.16504190862178802, "negative": 0.009960344061255455, "neutral": 0.8249977231025696}}, "embedding": [-0.0034880246967077255, 0.014620039612054825, 0.026660751551389694, -0.07809572666883469, 0.01815911941230297, 0.018209608271718025, -0.12396013736724854, 0.19799870252609253, 0.1257900446653366, 0.024073055014014244, -0.02599387615919113, 0.08164642751216888, 0.015504859387874603, 0.02617615833878517, -0.03631817176938057, 0.06932047009468079, -0.010803420096635818, 0.040778327733278275, -0.10653968155384064, 0.01728173904120922, 0.0060345930978655815, 0.03550675883889198, 0.13132643699645996, 0.03236710652709007, 0.039441950619220734, -0.06131923943758011, -0.14421263337135315, 0.05793315917253494, -0.04046044498682022, 0.0687716007232666, 0.13361923396587372, 0.20458835363388062, -0.04029235243797302, 0.021482739597558975, 0.04314049705862999, 0.008480897173285484, -0.19148492813110352, 0.11887985467910767, -0.12631618976593018, -0.05242081731557846, -0.008872455917298794, 0.060401640832424164, -0.1077733039855957, 0.14013488590717316, 0.05098458379507065, -0.2054096758365631, -0.31181684136390686, 0.025752251967787743, -0.015020597726106644, 0.19311563670635223, 0.0127828074619174, -0.1023356020450592, -0.06171448156237602, 0.21092337369918823, -0.06366774439811707, 0.04540223255753517, -0.11725389957427979, -0.04586678743362427, 0.03585940599441528, -0.06193752586841583, -0.03096434473991394, -0.1186198890209198, -0.09226247668266296, -0.04635460674762726, 0.13171979784965515, 0.04129863530397415, 0.12288489937782288, -0.1422555297613144, -0.0723743736743927, 0.03264722600579262, 0.023760877549648285, -0.00506711658090353, -0.014203749597072601, 0.2262582927942276, -0.12223542481660843, 0.09799916297197342, 0.1601540744304657, 0.032438576221466064, 0.024248864501714706, -0.04662290960550308, 0.0013323985040187836, 0.04536917805671692, 0.005834133364260197, -0.020510617643594742, -0.002119523473083973, -0.051824476569890976, -0.021888572722673416, 0.18019413948059082, 0.10154423117637634, 0.02947756089270115, 0.045087628066539764, 0.064910888671875, 0.05006081238389015, 0.08922562003135681, 0.033439114689826965, -0.05845852568745613, -0.05799175798892975, 0.03817106783390045, 0.09648691862821579, -0.07596311718225479, 0.09571554511785507, -0.15250100195407867, 0.0020697787404060364, -0.044027179479599, -0.10508424043655396, -0.058098550885915756, 0.01769736409187317, -0.06610999256372452, -0.0852503627538681, 0.03798278421163559, -0.04362080246210098, 0.00621529296040535, 0.21741002798080444, -0.05077406018972397, -0.06252201646566391, 0.2978735566139221, -0.08794347941875458, 0.05282309651374817, 0.22938385605812073, -0.06675104796886444, 0.08867360651493073, -0.06726613640785217, 0.03919157385826111, -0.08808660507202148, 0.10833217203617096, 0.08609984815120697, 0.04199059307575226, 1.3668203092876185e-32, -0.04240749031305313, -0.08603817224502563, -0.0018548406660556793, 0.1474231332540512, -0.006013563834130764, -0.00630026264116168, 0.1725688874721527, -0.03837057948112488, -0.19347867369651794, -0.19154007732868195, -0.13775883615016937, 0.10454465448856354, -0.06704053282737732, 0.01693013496696949, -0.10181863605976105, -0.08015115559101105, -0.02142452262341976, 0.062259964644908905, -0.05128508806228638, -0.005494077689945698, -0.015324334613978863, -0.0029608923941850662, -0.02848450466990471, -0.024084586650133133, -0.027466990053653717, -0.06667894124984741, -0.06816614419221878, 0.05691321939229965, -0.041944533586502075, 0.055261895060539246, -0.05411238223314285, 0.13072267174720764, -0.07237590104341507, -0.07233116775751114, -0.04183783382177353, -0.011684052646160126, 0.023685049265623093, -0.01658383198082447, 0.14280930161476135, 0.1302897036075592, -0.04556979238986969, 0.11365403234958649, 0.012685969471931458, -0.12805473804473877, -0.015133115462958813, -0.2614673376083374, -0.10656309127807617, 0.009520253166556358, -0.013639958575367928, 0.026542777195572853, 0.05702689290046692, -0.12387218326330185, -0.09402135759592056, -0.04177895188331604, -0.07773274183273315, 0.04942595958709717, -0.14399200677871704, -0.04018137976527214, -0.04690553992986679, 0.04538886249065399, 0.018114466220140457, 0.048832546919584274, -0.0012997575104236603, 0.0958176776766777, -0.011971672996878624, 0.06240003556013107, -0.07466911524534225, -0.12597006559371948, -0.034680746495723724, 0.08140464127063751, 0.008549895137548447, -0.05589998513460159, 0.15154731273651123, -0.0823746919631958, 0.09896206855773926, -0.14669586718082428, 0.1658584475517273, 0.225856214761734, -0.05324839800596237, 0.17923623323440552, 0.02829950861632824, 0.058090757578611374, -0.24882587790489197, 0.12369287759065628, 0.008954642340540886, -0.21156731247901917, 0.08026142418384552, 0.030282212421298027, -0.16402652859687805, -0.09324638545513153, 0.156690314412117, -0.1614176630973816, 0.008644364774227142, 0.11740536987781525, 0.124906525015831, -1.245935849795313e-32, -0.005326013080775738, 0.031100986525416374, 0.11595281958580017, -0.031483814120292664, -0.028573952615261078, 0.07568053901195526, 0.01945149339735508, -0.04974878579378128, 0.035829465836286545, -0.2124861180782318, 0.04869997501373291, 0.05070731043815613, 0.0033827070146799088, -0.034026242792606354, -0.17807188630104065, -0.019982408732175827, -0.03231973946094513, -0.07992536574602127, -0.17441508173942566, 0.028738435357809067, 0.09564492106437683, 0.06817307323217392, -0.09492198377847672, 0.04989374428987503, -0.09950760006904602, -0.006026695482432842, 0.11328789591789246, 0.11768846958875656, 0.0012906752526760101, -0.10654696822166443, -0.04939199984073639, -0.025777574628591537, -0.16892680525779724, 0.10816396772861481, 0.061751510947942734, -0.05835822969675064, 0.20331048965454102, -0.08469781279563904, -0.04451989382505417, -0.14133751392364502, 0.04865802824497223, 0.08211421966552734, -0.06429193913936615, 0.014158799313008785, -0.005434003658592701, 0.07235293090343475, 0.13845518231391907, -0.10332561284303665, 0.09443835914134979, 0.002973850117996335, -0.011777060106396675, 0.0939287394285202, -0.030639827251434326, 0.07046198099851608, 0.06353150308132172, -0.028324052691459656, 0.030093073844909668, -0.06435313075780869, -0.1812496781349182, 0.01667344570159912, 0.06864435225725174, 0.10314901173114777, -0.00836179405450821, -0.07924547791481018, 0.08618621528148651, 0.1557876467704773, 0.0212714746594429, 0.05392187461256981, 0.09124387800693512, -0.08171005547046661, -0.16986504197120667, 0.0026892847381532192, -0.03729173168540001, -0.16357946395874023, 0.02879144810140133, 0.07578295469284058, -0.012366797775030136, -0.04466043785214424, -0.020120298489928246, -0.06558610498905182, -0.08558516949415207, -0.06724181026220322, -0.08506960421800613, -0.05531802773475647, 0.09350554645061493, 0.05002729222178459, -0.010670240968465805, 0.015840845182538033, 0.0875878632068634, 0.055222287774086, -0.06180334836244583, -0.07222293317317963, -0.010189443826675415, -0.0026370370760560036, 0.038084715604782104, -1.0056511001721447e-07, 0.07954239845275879, -0.06130809336900711, -0.021696288138628006, -0.05784233286976814, 0.0765165463089943, -0.031767282634973526, -0.014737526886165142, 0.03625008463859558, 0.05193397402763367, 0.1670747697353363, 0.09179336577653885, 0.15740710496902466, -0.10024110972881317, -0.06316084414720535, -0.0491739958524704, 0.045829884707927704, -0.03330269083380699, 0.015037953853607178, -0.013293988071382046, 0.0036347992718219757, -0.15856701135635376, -0.03612520545721054, 0.031776510179042816, -0.05775431543588638, -0.010305969044566154, -0.03735918179154396, 0.029756946489214897, 0.11518461257219315, 0.08771055936813354, -0.09257794916629791, -0.10326685011386871, -0.11756876111030579, -0.027065947651863098, -0.004446952138096094, -0.057462140917778015, -0.06292517483234406, 0.08541947603225708, 0.003532474860548973, 0.11525189876556396, 0.1667405366897583, 0.146681010723114, 0.012517783790826797, 0.016418810933828354, 0.03193236514925957, 0.007802145555615425, -0.06752792000770569, -0.13109120726585388, -0.03629928454756737, -0.04359772801399231, -0.10386071354150772, -0.0352201908826828, -0.14860981702804565, -0.0274212546646595, -0.12663976848125458, -0.041899971663951874, 0.14332687854766846, -0.05981894209980965, 0.02871333807706833, 0.09300020337104797, 0.027448497712612152, -0.004829077050089836, -0.03290608525276184, -0.01608140580356121, -0.004396989941596985], "changes": {"1wk": -12.857139329520963}}, {"text": "Genprex Advances Cancer Trials and Diabetes Therapy TipRanks Tue, Jan 14, 2025, 5:28 PM 1 min read In This Article: GNPX -7.84% https://www.tipranks.com/news/the-fly/intuitive-surgical-price-target-raised-to-622-from-561-at-btig Genprex ( (GNPX) ) has issued an announcement. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Genprex has provided updates on its clinical trials and diabetes gene therapy programs. The Acclaim-1 and Acclaim-3 clinical trials, which focus on different types of lung cancer, have received FDA Fast Track and Orphan Drug Designations, reflecting their potential significance in cancer treatment. Additionally, the company is progressing with its diabetes gene therapy program, currently in preclinical evaluation at the University of Pittsburgh, with plans to advance regulatory discussions in 2025. More about Genprex Genprex, Inc. operates in the biotechnology industry, focusing on developing gene therapies for oncology and diabetes. The company is working on innovative treatments like the REQORSA therapy for non-small cell lung cancer and small cell lung cancer, as well as developing gene therapies for Type 1 and Type 2 diabetes in collaboration with the University of Pittsburgh. YTD Price Performance: -13.33% Average Trading Volume: 9,934,103 Technical Sentiment Consensus Rating: Buy Current Market Cap: $6.64M Find detailed analytics on GNPX stock on TipRanks\u2019 Stock Analysis page . Trending Articles ZETA Lawsuit Alert! Class Action Filed Against Zeta Global Holdings Corp. (NYSE:ZETA) Upcoming Stock Splits This Week (January 13 to January 17) \u2013 Stay Invested Miffed With Musk\u2019s Pay, Europe\u2019s Largest Pension Fund Exits Tesla Holding View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2025-01-14T14:28:22+00:00", "sentiment": {"score": 0.051556793972849846, "confidence": 0.07047485560178757, "probabilities": {"positive": 0.07047485560178757, "negative": 0.01891806162893772, "neutral": 0.910607099533081}}, "embedding": [-0.09428185969591141, -0.08780023455619812, -0.00717577151954174, -0.04175574705004692, 0.04255908727645874, -0.034653015434741974, 0.03368299454450607, 0.20665277540683746, 0.06828979402780533, -0.03562522307038307, -0.12850335240364075, 0.26881667971611023, -0.01688213460147381, -0.024108191952109337, -0.14584988355636597, 0.00916291307657957, 0.05738907679915428, -0.03050205111503601, 0.015858246013522148, 0.054559748619794846, -0.037849344313144684, -0.0845709964632988, 0.23235906660556793, 0.05324087291955948, 0.06710145622491837, -0.04086878150701523, -0.03184471279382706, 0.03655584901571274, -0.12856028974056244, 0.02027161419391632, -0.009019335731863976, 0.1463412344455719, -0.043688755482435226, -0.04158864542841911, -0.14118462800979614, 0.04843110591173172, -0.08072977513074875, 0.09386926144361496, -0.07478567212820053, -0.022191716358065605, 0.08033589273691177, -0.015379139222204685, -0.1720084398984909, 0.12350503355264664, 0.10165020078420639, -0.23227104544639587, -0.22449491918087006, -0.0256106685847044, 0.05353722721338272, 0.23612040281295776, -0.2529676854610443, -0.1851288080215454, 0.08776096254587173, 0.015246469527482986, -0.04982535541057587, 0.04409893602132797, -0.15911689400672913, -0.1191723570227623, 0.06041324511170387, -0.05326829105615616, 0.02454390563070774, -0.14545679092407227, 0.016583390533924103, -0.030187711119651794, 0.1909133642911911, -0.01711161434650421, 0.06432696431875229, 0.045344579964876175, -0.09183340519666672, -0.12903915345668793, 0.1267463117837906, -0.012618170119822025, -0.05847146362066269, 0.1871751844882965, -0.1751394122838974, 0.19895139336585999, 0.029069898650050163, 0.09983251243829727, 0.10206586122512817, -0.008198914118111134, 0.0450393445789814, -0.02153838239610195, 0.12124154716730118, 0.10182145982980728, -0.04814695566892624, -0.015211059711873531, 0.15786385536193848, 0.14776010811328888, 0.07213394343852997, 0.015315897762775421, -0.0020709349773824215, 0.04469860717654228, -0.02550460956990719, 0.11955951154232025, -0.02794334478676319, 0.008052261546254158, -0.11448279768228531, -0.11348680406808853, 0.06556455045938492, -0.05726049840450287, 0.09844477474689484, -0.011725050397217274, -0.005851876921951771, -0.03863009810447693, -0.09829894453287125, -0.10388903319835663, 0.04484434798359871, -0.054676927626132965, 0.06486436724662781, 0.034031741321086884, -0.09680865705013275, 0.1996099203824997, -0.009135954082012177, 0.01941773295402527, -0.2052352875471115, 0.312273234128952, -0.11779755353927612, 0.01959906332194805, 0.2284490168094635, 0.013401436619460583, 0.028369983658194542, 0.016018128022551537, -0.004804723896086216, -0.06459709256887436, 0.12708121538162231, 0.12685289978981018, -0.17467615008354187, 6.719956636869433e-33, -0.07858668267726898, -0.0002478254900779575, 0.036427851766347885, 0.07854078710079193, -0.051239531487226486, 0.05249643698334694, 0.11362909525632858, -0.011111264117062092, -0.3211177587509155, -0.12636145949363708, -0.2485298365354538, 0.07032173871994019, -0.05365169793367386, 0.08090157806873322, -0.07166390120983124, -0.12426523864269257, 0.014422345906496048, -0.007206919137388468, 0.037812039256095886, -0.011676264926791191, 0.07275842875242233, 0.054489947855472565, 0.049343451857566833, -0.06016194075345993, -0.021247103810310364, -0.0011783171212300658, -0.22009453177452087, 0.007439577020704746, 0.09998507052659988, 0.05834397301077843, -0.09798076003789902, 0.03892030194401741, 0.05436800792813301, -0.10027774423360825, -0.010429260320961475, -0.1268860548734665, -0.09053166210651398, -0.11974546313285828, 0.08930783718824387, 0.0602487251162529, -0.0704444944858551, 0.15480679273605347, -0.01723964884877205, -0.22687572240829468, -0.006170232780277729, 0.01795065402984619, -0.11936619132757187, -0.025440145283937454, -0.024400915950536728, 0.009623173624277115, -0.041141707450151443, 0.00753635773435235, -0.04034502059221268, 0.01529721263796091, -0.018520649522542953, 0.06679551303386688, -0.10572271794080734, -0.08098462969064713, -0.035694073885679245, 0.06903426349163055, -0.024443333968520164, 0.181371808052063, -0.021771857514977455, -0.048282694071531296, -0.19748514890670776, 0.12651315331459045, -0.034829314798116684, 0.04567662999033928, -0.10745527595281601, 0.23465974628925323, 0.09020654857158661, 0.0040841917507350445, 0.10102734714746475, -0.026277869939804077, 0.0730121061205864, -0.12243862450122833, 0.03443029895424843, 0.09104252606630325, 0.06105310097336769, 0.058080218732357025, 0.06987205892801285, -0.016500676050782204, -0.10070491582155228, 0.06833623349666595, -0.00129812047816813, -0.11052641272544861, -0.049558911472558975, -0.004904417786747217, -0.08694561570882797, -0.08014198392629623, -0.004044065251946449, -0.019616423174738884, -0.08569840341806412, 0.08565925806760788, -0.0895736813545227, -8.756002483937885e-33, -0.07970620691776276, 0.005747086368501186, 0.11118976026773453, 0.023451825603842735, -0.003812244860455394, 0.05004880577325821, 0.004900155123323202, -0.15615791082382202, 0.09563719481229782, -0.023548834025859833, 0.08673333376646042, 0.1811205893754959, 0.003608961123973131, 0.04927999526262283, -0.0809563621878624, -0.003794749965891242, -0.07494093477725983, -0.09259659796953201, -0.17533111572265625, -0.13208448886871338, 0.05289044976234436, 0.19591177999973297, -0.07062496989965439, 0.1440446972846985, -0.010999965481460094, 0.024176303297281265, 0.2191663533449173, 0.19505874812602997, -0.042107295244932175, -0.09653356671333313, -0.11305668205022812, 0.08043841272592545, -0.17360685765743256, 0.10471715778112411, 0.10039491951465607, -0.012033882550895214, 0.12139332294464111, -0.19907845556735992, 0.043344538658857346, -0.039634205400943756, -0.010235529392957687, 0.027290111407637596, -0.01796824298799038, -0.010776343755424023, 0.11456298828125, 0.06178976595401764, 0.03699704632163048, 0.06255195289850235, 0.22008569538593292, 0.060937583446502686, -0.05172690749168396, 0.13163024187088013, -0.019167877733707428, 0.0728578269481659, -0.07242479175329208, -0.1268559843301773, 0.009382453747093678, -0.05603984743356705, -0.19879695773124695, 0.026343638077378273, 0.027894040569663048, 0.058921508491039276, 0.001119983266107738, 0.07371797412633896, -0.03565593436360359, 0.049403343349695206, 0.07961568981409073, 0.010484136641025543, 0.05506274849176407, 0.031129678711295128, -0.03815878927707672, -0.03787124529480934, 0.03695349395275116, -0.14852674305438995, -0.0558045357465744, 0.1570768654346466, 0.022862760350108147, -0.04344659298658371, -0.07575252652168274, -0.027421925216913223, 0.10688571631908417, 0.0034771054051816463, 0.04932151734828949, -0.07037873566150665, 0.06436250358819962, 0.1521265208721161, 0.04524146392941475, 0.03132185712456703, -0.052618857473134995, 0.010546027682721615, -0.07165578007698059, -0.1485951989889145, -0.0940934270620346, -0.006479930132627487, 0.030837418511509895, -9.997948069440099e-08, 0.07181873172521591, -0.07750643044710159, 0.06911361217498779, -0.03859324008226395, 0.046582549810409546, -0.06673542410135269, -0.09791731089353561, 0.06208430230617523, 0.08558164536952972, 0.16496773064136505, 0.045000698417425156, 0.21013382077217102, -0.2741755545139313, -0.03274448588490486, -0.03125987946987152, -0.11721833795309067, -0.1329316347837448, 0.10932182520627975, -0.0614568293094635, -0.028068935498595238, -0.07480591535568237, 0.10037324577569962, 0.0603218711912632, -0.005278059281408787, 0.017572710290551186, -0.15320353209972382, 0.04176931083202362, -0.030680926516652107, 0.1185600757598877, -0.0674378052353859, -0.03657263144850731, -0.030037542805075645, 0.10239937156438828, 0.042484402656555176, -0.051842477172613144, -0.08192027360200882, 0.04344562441110611, 0.17965641617774963, 0.10079851001501083, 0.09818083047866821, 0.08868205547332764, -0.07451754808425903, -0.0025968030095100403, -0.05532180145382881, -0.12969687581062317, -0.03224974870681763, -0.0658702701330185, -0.05417528375983238, 0.13287924230098724, -0.05819467082619667, 0.04005549103021622, -0.0791633129119873, -0.06774716824293137, -0.07764837145805359, 0.025400198996067047, 0.15386730432510376, -0.2711576223373413, -0.024384239688515663, -0.0484137088060379, -0.10488635301589966, 0.04241366684436798, -0.2595807611942291, 0.04828464239835739, 0.13689519464969635], "changes": {"1wk": -2.4390172986737966}}, {"text": "Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire Mon, Jan 6, 2025, 5:15 PM 5 min read In This Article: GNPX -7.84% AUSTIN, Texas , Jan. 6, 2025 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating in investor, industry and business development meetings at the 43 rd Annual J.P. Morgan Healthcare Conference, taking place Jan. 13-16, 2025 in San Francisco, California . (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.) In attendance will be Ryan Confer , President, Chief Executive Officer and Chief Financial Officer; Mark Berger , MD, Chief Medical Officer; and Thomas Gallagher , Senior Vice President of Intellectual Property and Licensing. Throughout the duration of the conference, Genprex executives will be available to conduct one-on-one meetings with industry and investor groups to provide an overview of the Company's gene therapies for cancer and diabetes. For those interested in meeting Genprex management during the conference, please request a meeting through Investor Relations at investors@genprex.com . About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex \u00ae Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa \u00ae Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Story Continues Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website , registering for Email Alerts and by following Genprex on Twitter , Facebook and LinkedIn . Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under \"Item 1A \u2013 Risk Factors\" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023 . Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications, the timing and success of Genprex's clinical trials and regulatory approvals, the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to\u00a0maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations investors@genprex.com GNPX Media Contact Kalyn Dabbs media@genprex.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/genprex-to-participate-at-the-43rd-annual-jp-morgan-healthcare-conference-302342275.html SOURCE Genprex, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2025-01-06T14:15:00+00:00", "sentiment": {"score": 0.060867488384246826, "confidence": 0.07188061624765396, "probabilities": {"positive": 0.07188061624765396, "negative": 0.011013127863407135, "neutral": 0.9171062707901001}}, "embedding": [-0.10556922852993011, -0.02177862823009491, 0.045329704880714417, -0.011779990047216415, -0.05494466423988342, -0.021053075790405273, -0.0018507903441786766, 0.09335258603096008, 0.08203337341547012, -0.0861850306391716, -0.1536034494638443, 0.18964113295078278, 0.03902397304773331, -0.03447207808494568, -0.03342553228139877, 0.021889902651309967, 0.02751976065337658, 0.04434174299240112, -0.014129094779491425, 0.08546727895736694, 0.05668691545724869, -0.049520812928676605, 0.0994938388466835, 0.04614318162202835, -0.055999405682086945, 0.005930772982537746, -0.025290116667747498, 0.09174052625894547, -0.07692532241344452, 0.029772713780403137, 0.07757130265235901, 0.10743560642004013, 0.011317350901663303, -0.09050866961479187, -0.06498885899782181, 0.12641331553459167, -0.0746142715215683, 0.0845228061079979, -0.12788812816143036, -0.12802821397781372, 0.024372441694140434, -0.036881621927022934, -0.09095621109008789, 0.1407502144575119, 0.1319797933101654, -0.2017677128314972, -0.1149139329791069, 0.0032530752941966057, 0.007895047776401043, 0.18851366639137268, -0.16636380553245544, -0.19692549109458923, 0.10937988758087158, 0.0417938157916069, 0.008847453631460667, 0.09428814053535461, -0.18127724528312683, -0.11622282862663269, 0.03260244056582451, -0.08918216824531555, -0.01901140995323658, -0.12215414643287659, -0.02737032249569893, 0.04517563432455063, 0.1048184335231781, 0.0676269680261612, 0.11842350661754608, 0.03298281878232956, -0.02683868259191513, -0.15108951926231384, 0.024138040840625763, 0.034785885363817215, -0.03070295788347721, 0.23252737522125244, -0.057069081813097, 0.1378391683101654, 0.15085972845554352, 0.06001812964677811, 0.1396304965019226, -0.07100151479244232, 0.06425963342189789, 0.09382116794586182, 0.09407103061676025, 0.09551592171192169, -0.0713086947798729, 0.03270231559872627, 0.16665686666965485, 0.10472813248634338, 0.07471071183681488, -0.015215648338198662, -0.1374567598104477, 0.03165054693818092, 0.0719108134508133, 0.048391085118055344, -0.05539906769990921, 0.028582904487848282, -0.12284399569034576, -0.0961485207080841, 0.09657648205757141, -0.04173867404460907, 0.03274357318878174, -0.030200811102986336, -0.004594593308866024, -0.04615182429552078, -0.14620527625083923, -0.0542822889983654, -0.0989004448056221, 0.012351259589195251, 0.022158969193696976, 0.10653427243232727, -0.08025192469358444, 0.11419492214918137, 0.04025235399603844, -0.04280010610818863, -0.10005824267864227, 0.18939116597175598, -0.12249134480953217, 0.05044516548514366, 0.24041107296943665, -0.10126324743032455, -0.051161907613277435, 0.03439762070775032, -0.033152785152196884, -0.07591591030359268, 0.07924108952283859, 0.07846961170434952, -0.1391354501247406, 7.554905866154688e-33, -0.13243131339550018, -0.0857868492603302, 0.12123536318540573, 0.16282664239406586, 0.05875551328063011, 0.00675706472247839, 0.11885106563568115, -0.017149250954389572, -0.23449790477752686, -0.1169581487774849, -0.14631646871566772, 0.01540425606071949, 0.0022278567776083946, 0.18176373839378357, -0.03526581451296806, -0.1271946132183075, 0.0002119988203048706, 0.0033177779987454414, 0.007119446527212858, -0.011262791231274605, -0.03234339505434036, 0.05811898037791252, 0.052210718393325806, 0.05782436951994896, 0.0024878624826669693, 0.03864304721355438, -0.06773856282234192, 0.058534055948257446, 0.1557897925376892, 0.045824360102415085, -0.12419495731592178, -0.010776408016681671, 0.0676499605178833, -0.13921891152858734, -0.006802180781960487, -0.050179623067379, -0.06361114978790283, -0.1087886393070221, 0.10887987911701202, 0.12909433245658875, -0.10820962488651276, 0.07151216268539429, -0.07528619468212128, -0.10574058443307877, 0.013957949355244637, -0.03324109688401222, -0.01595441624522209, 0.020323580130934715, 0.007336089387536049, 0.027440328150987625, -0.0172424279153347, 0.05082105100154877, -0.06218855455517769, -0.0025324635207653046, -0.05959508195519447, 0.01688719168305397, -0.09850646555423737, -0.05241746827960014, 0.0013626236468553543, 0.09220215678215027, -0.040824826806783676, 0.23678699135780334, -0.04837736859917641, 0.0760369747877121, -0.031205132603645325, 0.08168799430131912, -0.04188916087150574, -0.05063725635409355, -0.03417513519525528, 0.10318149626255035, 0.08295971900224686, 0.022770673036575317, 0.026637716218829155, -0.06121624633669853, -0.01230728067457676, -0.09486284106969833, 0.00734095461666584, 0.11883299052715302, 0.03554713726043701, 0.10270790010690689, -0.0548354797065258, 0.0733526274561882, -0.17765483260154724, 0.12182917445898056, 0.011554207652807236, -0.09848204255104065, 0.0018422417342662811, 0.013881342485547066, -0.10888883471488953, -0.014813223853707314, 0.09051548689603806, -0.09627683460712433, 0.016682825982570648, 0.1216212585568428, -0.0664360299706459, -8.64428864362352e-33, -0.07858693599700928, -0.03730611503124237, 0.05986988544464111, 0.013749079778790474, -0.04307534173130989, 0.009730150923132896, 0.06919822096824646, -0.17371678352355957, 0.04882853478193283, -0.11022836714982986, 0.03533367067575455, 0.11919710040092468, -0.014060069806873798, -0.026900123804807663, -0.11421573907136917, 0.011827331967651844, -0.027942299842834473, -0.10661134123802185, -0.17315752804279327, -0.022901011630892754, 0.04992659389972687, 0.26964282989501953, -0.044814858585596085, 0.08944599330425262, 0.010323930531740189, -0.01882144622504711, 0.21280518174171448, 0.22741273045539856, 0.01513171661645174, -0.1358092725276947, -0.09350976347923279, 0.025965407490730286, -0.22541260719299316, 0.03536031022667885, 0.059171535074710846, -0.050993382930755615, 0.07676857709884644, -0.15293879806995392, 0.07857304066419601, -0.13537660241127014, 0.02588725835084915, 0.008860418573021889, -0.12584246695041656, 0.04476373642683029, 0.009675253182649612, 0.0686412900686264, -0.02791905403137207, -0.033306509256362915, 0.1836855709552765, 0.025842465460300446, -0.11914816498756409, 0.0036330390721559525, 0.0047988491132855415, -0.02166249230504036, -0.050703778862953186, -0.12072852998971939, -0.010289342142641544, -0.038031794130802155, -0.004033842124044895, 0.015342005528509617, 0.013478504493832588, -0.037074118852615356, 0.09605788439512253, 0.07198251783847809, 0.03473721817135811, 0.07507865130901337, 0.08770009875297546, 0.0076894029043614864, 0.05984225869178772, -0.05902031064033508, -0.030183663591742516, 0.02304932102560997, -0.05113465338945389, -0.15367311239242554, -0.01245194673538208, 0.09781935065984726, -0.07693084329366684, -0.039035145193338394, -0.12386719882488251, -0.0255243182182312, 0.08122678101062775, -0.05077144131064415, -0.004091732203960419, -0.0024059731513261795, 0.08763879537582397, 0.08941681683063507, 0.030955443158745766, 0.04927971959114075, 0.013995182700455189, 0.054897554218769073, -0.08473047614097595, -0.07685475051403046, -0.12215027213096619, 0.037770215421915054, 0.012209607288241386, -1.0028510644133348e-07, 0.04780580475926399, -0.065384142100811, 0.02941245585680008, -0.11106358468532562, 0.004565814509987831, -0.05358229577541351, -0.05748293921351433, -0.018965188413858414, 0.08155035972595215, 0.17175346612930298, 0.0829550102353096, 0.17443621158599854, -0.13987620174884796, 0.027137506753206253, -0.11658056080341339, -0.022463656961917877, -0.11052408814430237, 0.06984801590442657, -0.08074142783880234, -0.10401009023189545, -0.13873304426670074, 0.025216389447450638, -0.05318771302700043, 0.07008511573076248, 0.11313693225383759, -0.17663702368736267, 0.12598365545272827, -0.029969990253448486, 0.039140667766332626, -0.12855491042137146, -0.06466677039861679, -0.05756891146302223, 0.04487726092338562, 0.09809121489524841, -0.004800646565854549, -0.14321377873420715, 0.050041016191244125, 0.175120547413826, 0.10273639857769012, 0.06295956671237946, 0.06308150291442871, -0.03804824501276016, 0.008033504709601402, -0.007021915167570114, -0.14918768405914307, -0.0176849327981472, -0.0825532078742981, 0.003494496922940016, 0.006888492498546839, -0.033839330077171326, -0.07169299572706223, -0.003424542024731636, -0.04234917461872101, -0.05792352184653282, -0.04337291792035103, 0.12715111672878265, -0.15455585718154907, 0.0021475576795637608, 0.05926516279578209, -0.04753049463033676, 0.027301175519824028, -0.07590927928686142, 0.126461923122406, 0.024182766675949097], "changes": {"1wk": -10.85714612688337}}, {"text": "PREMIUM Genprex Completes Phase 1 Dose Escalation in Trial of Reqorsa Gene Therapy to Treat Lung Cancer MT Newswires Mon, Dec 16, 2024, 5:58 PM In This Article: GNPX -7.84% Genprex (GNPX) said Monday that it has completed the phase 1 dose escalation portion of a trial of R PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2024-12-16T14:58:09+00:00", "sentiment": {"score": 0.06663496140390635, "confidence": 0.07711651176214218, "probabilities": {"positive": 0.07711651176214218, "negative": 0.010481550358235836, "neutral": 0.9124019742012024}}, "embedding": [-0.0735255628824234, -0.0682380199432373, 0.02774936892092228, -0.04402393847703934, 0.06516706943511963, -0.021921252831816673, -0.08160021901130676, 0.1305442750453949, -0.053482070565223694, -0.008975665085017681, -0.02598467282950878, 0.30867648124694824, 0.07684309035539627, 0.04501892626285553, 0.08265309780836105, 0.031545184552669525, 0.11515571922063828, 0.05129842087626457, 0.08755336701869965, 0.038170378655195236, -0.08720147609710693, 0.05600302666425705, 0.1335759311914444, 0.11668568849563599, 0.11624548584222794, 0.05647556483745575, -0.12366637587547302, 0.029016414657235146, 0.17402279376983643, 0.016954174265265465, 0.17466171085834503, 0.12305119633674622, -0.05648258328437805, -0.04298552870750427, -0.037411633878946304, 0.07739971578121185, -0.06535892188549042, 0.08798429369926453, -0.2075922191143036, 0.013267718255519867, 0.09450143575668335, -0.09762120991945267, -0.15567660331726074, 0.242965430021286, 0.12943750619888306, -0.15170881152153015, -0.2804710268974304, 0.06586059927940369, 0.06008947640657425, 0.24339698255062103, 0.03448517248034477, -0.3051181137561798, -0.024473123252391815, 0.07075203210115433, -0.025113988667726517, 0.04053314030170441, -0.21298472583293915, -0.16637489199638367, 0.09136296063661575, -0.009305199608206749, -0.10110444575548172, -0.23313896358013153, -0.09601540118455887, -0.02847200259566307, 0.10801048576831818, 0.09886448085308075, 0.21114666759967804, -0.15118807554244995, 0.06835737079381943, -0.035331107676029205, 0.05240288004279137, 0.11709584295749664, -0.006400496233254671, 0.04842761904001236, -0.16010065376758575, 0.19956538081169128, 0.07267769426107407, -0.016190486028790474, 0.0760442242026329, 0.006113000679761171, 0.06589537113904953, -0.04548443481326103, 0.03712693601846695, 0.09692560881376266, 0.01393915805965662, -0.14445793628692627, 0.021012553945183754, 0.03389087691903114, 0.11108765006065369, -0.07791000604629517, 0.12555380165576935, 0.05849722400307655, 0.11765053868293762, 0.12511922419071198, -0.14062950015068054, 0.060049355030059814, -0.18474076688289642, -0.11014526337385178, -0.018465330824255943, -0.10298009216785431, 0.06110243871808052, -0.1516401171684265, -0.02181551419198513, 0.050433047115802765, -0.29321107268333435, -0.23488450050354004, -0.01963409222662449, 0.09413305670022964, -0.14016123116016388, 0.029515177011489868, -0.05329647287726402, 0.10915063321590424, 0.3106461763381958, -0.10826067626476288, -0.1645473688840866, 0.35703521966934204, -0.10458642989397049, 0.11135447025299072, 0.1978248804807663, -0.14930950105190277, -0.0054048760794103146, -0.0259101502597332, -0.0013781138695776463, -0.1064244881272316, 0.1767653524875641, -0.04426422342658043, -0.06459365785121918, 1.380391244631068e-32, -0.10283501446247101, 0.05523845925927162, 0.08674826472997665, 0.07531305402517319, 0.0260348841547966, 0.13193480670452118, 0.17819304764270782, -0.07294193655252457, -0.19342434406280518, -0.24064259231090546, -0.1980973184108734, 0.14275607466697693, -0.11702213436365128, 0.11690056324005127, -0.16645054519176483, -0.1693151593208313, -0.09912652522325516, 0.1448996514081955, 0.06412220746278763, 0.08638764172792435, 0.10793644189834595, -0.10343994945287704, -0.0029134759679436684, -0.04185368865728378, -0.15471164882183075, 0.09460001438856125, 0.04059121385216713, -0.06018461287021637, 0.10664201527833939, 0.06981687247753143, -0.15045760571956635, 0.07048813998699188, -0.10669643431901932, 0.08424253761768341, -0.018249250948429108, 0.059783685952425, -0.02147776260972023, -0.10378466546535492, 0.02992461808025837, 0.045686665922403336, -0.10675177723169327, 0.1041160374879837, -0.050292886793613434, -0.20844429731369019, 0.0012763498816639185, -0.17895826697349548, -0.16682833433151245, -0.08931080251932144, 0.01824348233640194, 0.01222735084593296, 0.10184986889362335, 0.07122448086738586, -0.24184392392635345, -0.02454359270632267, -0.03216065466403961, -0.01779509335756302, -0.11490216851234436, 0.016447607427835464, -0.05563611909747124, -0.021080680191516876, 0.11685922741889954, 0.05807558074593544, -0.03188669681549072, -0.07257474958896637, -0.1161809042096138, 0.057755693793296814, -0.1371169239282608, -0.22365114092826843, -0.056620337069034576, 0.23622041940689087, 0.2618071138858795, -0.06560374051332474, 0.07212557643651962, -0.1157100722193718, -0.05493100360035896, -0.09506000578403473, 0.04379397630691528, 0.24301986396312714, 0.22213679552078247, 0.21485398709774017, -0.12168559432029724, 0.031437359750270844, -0.18084272742271423, 0.20540378987789154, 0.0856969952583313, -0.1265159696340561, 0.06474929302930832, -0.018515869975090027, -0.08973172307014465, 0.018385617062449455, 0.11434720456600189, -0.19966931641101837, 0.030891109257936478, 0.1612309217453003, -0.026820143684744835, -1.2620077963069308e-32, -0.09053690731525421, 0.02486046776175499, 0.11554650962352753, 0.08051781356334686, -0.11762800067663193, 0.04481323063373566, 0.018424618989229202, 0.10109374672174454, 0.2505720555782318, 0.021007711067795753, 0.199210062623024, 0.14508461952209473, -0.07684534788131714, 0.1225212812423706, -0.004216659814119339, -0.1030006930232048, 0.051766298711299896, -0.14491991698741913, -0.21888212859630585, -0.05162719637155533, 0.04188292473554611, 0.08675370365381241, 0.002216258319094777, 0.20940527319908142, 0.07710638642311096, -0.16191579401493073, 0.2829734683036804, 0.2618865668773651, 0.011995982378721237, -0.1597733199596405, -0.16052165627479553, -1.629881990083959e-05, -0.2603175640106201, 0.12789730727672577, 0.07387024164199829, 0.04483376815915108, 0.2777746915817261, 0.024931157007813454, -0.04139422997832298, -0.14453531801700592, -0.006233702413737774, 0.018333258107304573, -0.15554657578468323, 0.09898468852043152, 0.01067335531115532, 0.07437153905630112, 0.14165841042995453, -0.03217068314552307, 0.21295267343521118, -0.03446357697248459, -0.08571681380271912, 0.06933366507291794, -0.016802599653601646, 0.0408671535551548, -0.03503398969769478, -0.1365460604429245, -0.009709319099783897, -0.020268158987164497, -0.1258445382118225, 0.07715924829244614, 0.11861347407102585, 0.1147276759147644, -0.2730843424797058, -0.1578252762556076, 0.010040163062512875, 0.10210433602333069, 0.11881477385759354, -0.013694890774786472, 0.1613786220550537, 0.008465228602290154, -0.10256099700927734, -0.0657549500465393, 0.00944657251238823, -0.16709257662296295, 0.03518293797969818, 0.0505019873380661, -0.057228635996580124, -0.06279445439577103, -0.05324717238545418, -0.2144957184791565, 0.09105712175369263, -0.0618446059525013, -0.09462504833936691, -0.04571351408958435, 0.07138597965240479, -0.060180146247148514, 0.08350487053394318, 0.07877253741025925, -0.009611792862415314, 0.10847566276788712, -0.14068995416164398, -0.11152444779872894, -0.18171073496341705, 0.11114677041769028, 0.1160074844956398, -9.946694490281516e-08, 0.04233346879482269, -0.03949951007962227, 0.07186423242092133, -0.11835792660713196, 0.23673437535762787, 0.0392487607896328, -0.08411438763141632, 0.05176916718482971, 0.02277669869363308, 0.1977892369031906, 0.06283626705408096, 0.11729740351438522, 0.01611836440861225, -0.030860334634780884, -0.0677124634385109, 0.028269467875361443, -0.025983845815062523, 0.09542074799537659, -0.020815663039684296, -0.16096092760562897, -0.11870051175355911, 0.01153538003563881, 0.09167171269655228, -0.09658832848072052, -0.07943892478942871, -0.07562558352947235, 0.0809452161192894, 0.06707800179719925, 0.1281590312719345, -0.15394841134548187, -0.14145900309085846, -0.05887533351778984, 0.026494471356272697, 0.07592042535543442, -0.18595299124717712, -0.06138550862669945, 0.14098916947841644, 0.24684196710586548, 0.17147433757781982, -0.022320538759231567, 0.08648132532835007, -0.034011151641607285, 0.06961105763912201, 0.06037754938006401, -0.2148217111825943, -0.007911251857876778, -0.23468364775180817, -0.12238817662000656, -0.0025508010294288397, -0.03715387359261513, 0.06477542221546173, -0.09191406518220901, 0.06266369670629501, -0.17111483216285706, -0.06683875620365143, 0.10193414241075516, -0.12737330794334412, -0.09453238546848297, 0.002174579305574298, 0.03423353657126427, 0.1129080280661583, -0.17747455835342407, 0.012720449827611446, -0.035469964146614075], "changes": {"1wk": -11.04761355480074, "1mo": -33.333331441122304}}, {"text": "Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa\u00ae Gene Therapy in Combination with Tecentriq\u00ae in Extensive Stage Small Cell Lung Cancer PR Newswire Mon, Dec 16, 2024, 5:15 PM 9 min read In This Article: GNPX -7.84% Genprex Completes Phase 1 Dose Escalation Portion of Acclaim-3 Clinical Trial Results from Phase 1 Dose Escalation Demonstrate Favorable Safety Profile of REQORSA and Tecentriq in ES-SCLC Patients AUSTIN , Texas , Dec. 16, 2024 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion of the Acclaim-3 clinical trial of Reqorsa\u00ae Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq\u00ae (atezolizumab) as maintenance therapy to treat patients with extensive stage small cell lung cancer (ES-SCLC). In addition, the Safety Review Committee (SRC) has approved the opening of the Phase 2 expansion portion of the trial. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.) The combination of REQORSA and atezolizumab previously received U.S. Food and Drug Administration's (FDA) Fast Track Designation for the treatment of the Acclaim-3 patient population, and the FDA has also granted Orphan Drug Designation to REQORSA for the treatment of SCLC. Based on full safety data, which showed no dose limiting toxicities (DLTs), the SRC determined that the Recommended Phase 2 Dose (RP2D) of REQORSA will be 0.12 mg/kg. This was the highest dose level delivered in the Phase 1 portion of the trial. The SRC also recommended the trial advance to the Phase 2 expansion portion of the study, which the Company has now opened for enrollment. \"We are pleased to complete the Phase 1 dose escalation portion of the Acclaim-3 clinical trial and to have now opened the Phase 2 expansion portion of Acclaim-3 for enrollment in the second half of 2024, in accordance with our previously disclosed guidance for timing and milestones,\" said Ryan Confer , President and Chief Executive Officer at Genprex. \"Our partnership with a large network of community-based oncology practices has allowed us to have successful enrollment rates, enabling Genprex to meet our 2024 timeline targets for this study. In adding multiple clinical trial sites to our Acclaim-3 study, we have been able to more efficiently and expeditiously accelerate the Acclaim-3 clinical trial.\u00a0Looking ahead, we believe this sets the stage for potential promising enrollment rates for the Phase 2 portion of the trial. Additionally, we will be submitting the results of the Phase 1 portion of the study to a clinical meeting and anticipate data presentation in 2025, and we remain encouraged by the early efficacy demonstrated in ES-SCLC patients.\" Story Continues Genprex previously reported the first patient treated in the Phase 1 dose escalation portion of the Acclaim-3 trial had a partial remission, which is defined as at least a thirty percent (30%) decrease in tumor size, from prior to the start of maintenance therapy to the time of the CT scan performed after two cycles of maintenance therapy. A CT scan performed after four cycles of maintenance therapy (three months), confirmed that the patient had a 30% decrease in tumor size in measurable lesions; however, one lesion not previously measurable had grown in size, thus leading to a conclusion of disease progression at that time. As the maintenance therapy consists of REQORSA and Tecentriq, and the patient had already received four cycles of Tecentriq during induction therapy and thus responses to Tecentriq would likely have occurred earlier, the Company believes this suggests that REQORSA may be providing clinical benefit. In the Phase 1 dose escalation portion of the Acclaim-3 clinical trial, patients were treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity was experienced. The primary endpoint of the Phase 1 escalation portion was to determine the Maximum Tolerated Dose (MTD) or RP2D. The SRC is comprised of three physicians who are principal investigators in the trial. Based on the preliminary safety data from patients in the 0.12 mg/kg dose level, the SRC recommended that the 0.12 mg/kg dose be the RP2D that will be used in the Phase 2 portion of the trial and that the Phase 2 trial be opened for enrollment. The Phase 1 dose escalation portion of the trial had two dose groups: 0.09 mg/kg and 0.12 mg/kg.The Phase 2 expansion portion will enroll approximately 50 patients at approximately 10 to 15 U.S sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. The primary endpoint of the Phase 2 portion is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up. Data presented at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics from studies in humanized mouse models of SCLC that use human H841 cells have shown that the combination of REQORSA and Tecentriq provides significantly better control of tumor burden than either agent alone.\u00a0The data from these studies also suggest that a combination treatment of REQORSA and Tecentriq can promote a significantly increased tumor cell killing effect in SCLC xenografts compared to that of Tecentriq alone. About Acclaim-3 The Acclaim-3 clinical trial is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company's lead drug candidate, Reqorsa\u00ae Gene Therapy, in combination with Genentech, Inc.'s Tecentriq\u00ae (atezolizumab) as maintenance therapy in patients with extensive stage small cell lung cancer (ES-SCLC) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex\u00ae Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa\u00ae Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website , registering for Email Alerts and by following Genprex on Twitter , Facebook and LinkedIn . Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under \"Item 1A \u2013 Risk Factors\" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023 . Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications, such as REQORSA in combination with other therapies in SCLC; the timing and success of Genprex's clinical trials and regulatory approvals, including, but not limited to, the Phase 1 dose escalation and the Phase 2 expansion portions of the Acclaim-3 trial; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to\u00a0maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations investors@genprex.com GNPX Media Contact Kalyn Dabbs media@genprex.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/genprex-receives-safety-review-committee-approval-to-advance-to-phase-2-portion-of-acclaim-3-clinical-trial-of-reqorsa-gene-therapy-in-combination-with-tecentriq-in-extensive-stage-small-cell-lung-cancer-302332325.html SOURCE Genprex, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2024-12-16T14:15:00+00:00", "sentiment": {"score": 0.5095036635175347, "confidence": 0.5196669697761536, "probabilities": {"positive": 0.5196669697761536, "negative": 0.010163306258618832, "neutral": 0.47016969323158264}}, "embedding": [-0.04245447367429733, 0.01499662734568119, -0.07947354018688202, -0.047030698508024216, -0.04436803236603737, -0.003744636196643114, -0.07675802707672119, 0.17792528867721558, 0.11639642715454102, 0.05958244577050209, -0.03538812696933746, 0.07321050018072128, 0.08794564008712769, 0.047939468175172806, -0.046384815126657486, 0.07310425490140915, 0.08483409881591797, 0.10514605045318604, -0.11089184135198593, 0.046504292637109756, 0.07547103613615036, 0.024749305099248886, 0.1280410885810852, 0.06993971765041351, 0.014754502102732658, -0.03239857405424118, -0.13922405242919922, 0.10294068604707718, -0.06400032341480255, -0.07644104957580566, 0.14063222706317902, 0.14763902127742767, -0.08615058660507202, -0.11296254396438599, 0.03215600922703743, -0.0021118000149726868, -0.10546684265136719, 0.058433156460523605, -0.15981870889663696, -0.040208473801612854, 0.012592234648764133, 0.05621098726987839, -0.14971694350242615, 0.12922540307044983, 0.03228427469730377, -0.20578183233737946, -0.2534593939781189, 0.0676737055182457, -0.0034928452223539352, 0.18679510056972504, -0.02112415060400963, -0.1574472188949585, -0.07875552773475647, 0.19308263063430786, -0.024839168414473534, 0.007535979151725769, -0.15731820464134216, -0.005597759038209915, 0.0460299551486969, 0.019592301920056343, -0.07960186898708344, -0.13318610191345215, -0.021634021773934364, -0.03728659451007843, 0.1415225714445114, 0.0012632221914827824, 0.010798252187669277, -0.21333961188793182, -0.05188015103340149, -0.011136683635413647, 0.06912705302238464, -0.028096076101064682, 0.028241200372576714, 0.16083726286888123, -0.08007119596004486, 0.09911838173866272, 0.11949657648801804, 0.03553124517202377, 0.038353919982910156, -0.0017511071637272835, 0.02948255091905594, 0.03663329780101776, 0.006427600979804993, 0.03452630341053009, 0.0082699004560709, -0.052839212119579315, -0.04857831448316574, 0.12835291028022766, 0.10690353810787201, 0.04886670410633087, 0.0603201650083065, 0.05651476979255676, 0.030058972537517548, 0.0683535486459732, 0.034195881336927414, -0.020458446815609932, -0.1225707083940506, -0.05487166717648506, 0.08056247234344482, -0.05969244986772537, 0.09014976024627686, -0.10982762277126312, -0.05306917428970337, -0.07197418808937073, -0.0764370784163475, -0.08588245511054993, 0.04499346762895584, -0.0007918309420347214, -0.0811254009604454, 0.03307858109474182, -0.042759403586387634, 0.03938812017440796, 0.21020649373531342, -0.05877435952425003, -0.09152622520923615, 0.31006449460983276, -0.0796482041478157, 0.03870837017893791, 0.19461384415626526, -0.12468816339969635, 0.05095238983631134, -0.04525630921125412, 0.04456958919763565, -0.14420081675052643, 0.1690700650215149, 0.05705095827579498, -0.029393795877695084, 1.4389849360421557e-32, -0.056041017174720764, 0.012148028239607811, 0.03253309428691864, 0.12963193655014038, 0.07321701943874359, 0.0585501492023468, 0.08679965138435364, 0.005769824609160423, -0.16263556480407715, -0.2025781124830246, -0.19614353775978088, 0.05607970058917999, -0.0362880639731884, 0.06683218479156494, -0.07067452371120453, -0.09935243427753448, -0.07554273307323456, 0.05422766134142876, -0.05650908499956131, 0.018442794680595398, -0.00759524991735816, -0.0310012586414814, -0.006154605653136969, -0.015288097783923149, -0.07553839683532715, 0.03216681256890297, -0.1061587929725647, 0.03846944123506546, 0.025002364069223404, 0.030428284779191017, -0.052298180758953094, 0.09036087989807129, -0.04433102905750275, -0.06142006069421768, -0.055941686034202576, -0.01107843965291977, -0.057316459715366364, -0.05709843337535858, 0.05829963833093643, 0.14942842721939087, -0.0248938649892807, 0.10633979737758636, -0.02241806499660015, -0.07327870279550552, 0.05075407400727272, -0.16634102165699005, -0.140053853392601, -0.0025964537635445595, 0.005532227456569672, 0.010294683277606964, 0.10768204927444458, -0.04580189287662506, -0.04073610529303551, 0.018866922706365585, -0.06728775054216385, 0.02007617987692356, -0.11949686706066132, 0.017163675278425217, -0.004552660509943962, 0.07466019690036774, -0.01639295369386673, 0.1366763710975647, -0.0019463584758341312, 0.04513207823038101, -0.041260767728090286, 0.04044041037559509, -0.09237630665302277, -0.08320724219083786, -0.04812179505825043, 0.08356806635856628, 0.0635543093085289, -0.031208544969558716, 0.17665469646453857, -0.08686235547065735, 0.09988783299922943, -0.12244713306427002, 0.11377470940351486, 0.26723358035087585, 0.045535095036029816, 0.018536996096372604, 0.007237155921757221, 0.034464236348867416, -0.16893669962882996, 0.13637974858283997, -0.06295643001794815, -0.16854453086853027, 0.011612458154559135, 0.033858343958854675, -0.10266169905662537, -0.009961039759218693, 0.15228721499443054, -0.08550283312797546, -0.02974441647529602, 0.12058351933956146, 0.04655759781599045, -1.2258725856838752e-32, -0.026120485737919807, 0.07150280475616455, 0.13342702388763428, -0.048246465623378754, -0.04611245542764664, 0.08017060160636902, 0.052474699914455414, -0.07645536959171295, 0.11602704972028732, -0.16380852460861206, 0.11764753609895706, 0.06410548835992813, -0.01475294679403305, -0.005818990059196949, -0.10110099613666534, -0.005908366292715073, -0.0019860807806253433, -0.03603167086839676, -0.19070054590702057, 0.005161380395293236, 0.06555578112602234, 0.1139492467045784, -0.11241723597049713, 0.08259879797697067, -0.014753714203834534, -0.032912321388721466, 0.1525029093027115, 0.05838639661669731, 0.054331500083208084, -0.07650405168533325, -0.03103182651102543, 0.004764084704220295, -0.249752938747406, 0.10944432020187378, 0.08022578060626984, -0.05443345010280609, 0.17785975337028503, -0.15057457983493805, -0.05327180027961731, -0.1476990282535553, 0.05701502785086632, 0.0924227386713028, -0.10028683394193649, 0.05353999510407448, 0.007068033330142498, 0.09929656982421875, 0.14575716853141785, -0.08649352192878723, 0.09755925834178925, -0.0018464494496583939, -0.07635661959648132, 0.004793955013155937, -0.04396466910839081, 0.13401925563812256, 0.032782845199108124, -0.028073478490114212, -0.0233708955347538, -0.08811357617378235, -0.13074764609336853, 0.05152090638875961, 0.047866493463516235, 0.10818734765052795, -0.03984414041042328, -0.09962965548038483, 0.14010939002037048, 0.1267097443342209, 0.02754782885313034, 0.0575963631272316, 0.1423751413822174, -0.055029142647981644, -0.15509340167045593, -0.030986694619059563, 0.009780848398804665, -0.14035138487815857, -0.03870510309934616, 0.07742644846439362, -0.025110401213169098, -0.08289484679698944, -0.08233128488063812, -0.1078244000673294, -0.01910863257944584, -0.0366765633225441, -0.0766216591000557, -0.07293795794248581, 0.1021297425031662, 0.044246092438697815, -0.011158598586916924, 0.03513175621628761, 0.02369251847267151, 0.08644676953554153, -0.06470288336277008, -0.051189620047807693, -0.03427154943346977, 0.11597543209791183, 0.13592855632305145, -1.0047543241853418e-07, 0.06723982095718384, -0.0624113492667675, -0.05564656853675842, -0.07504084706306458, 0.0563710480928421, -0.03588266670703888, -0.04462790861725807, 0.04846038296818733, 0.03208749368786812, 0.15831632912158966, 0.050111912190914154, 0.19809561967849731, -0.10334967076778412, -0.05370885878801346, -0.02945101261138916, 0.07027453184127808, -0.05415983125567436, 0.01101867388933897, 0.01397742796689272, -0.018722908571362495, -0.16058573126792908, -0.027690298855304718, -0.01021913904696703, -0.06408235430717468, -0.055458955466747284, -0.08927614986896515, 0.04717463254928589, 0.06445377320051193, 0.0601973719894886, -0.08110668510198593, -0.0971112996339798, -0.07668816298246384, -0.025966349989175797, 0.05867587774991989, -0.08047954738140106, -0.10503514111042023, 0.056346409022808075, 0.1474974900484085, 0.14009623229503632, 0.11693505942821503, 0.15864171087741852, -0.012132691219449043, 0.015316275879740715, 0.03965432569384575, -0.04458923637866974, -0.051628824323415756, -0.18914642930030823, -0.0376126728951931, -0.029402201995253563, -0.12029194831848145, -0.07091927528381348, -0.06402020901441574, 0.0059618111699819565, -0.16993500292301178, -0.04717637598514557, 0.10589472204446793, -0.12097382545471191, -0.00909140519797802, 5.6284479796886444e-05, -0.0009633051231503487, 0.049612514674663544, -0.0361306332051754, 0.08610424399375916, 0.018175184726715088], "changes": {"1wk": -13.333326899815829, "1mo": -29.714284838462323}}, {"text": "Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer PR Newswire Wed, Nov 20, 2024, 5:29 PM 7 min read In This Article: GNPX -7.84% License includes Genprex's Reqorsa \u00ae Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas , Nov. 20, 2024 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Michigan , granting Genprex a worldwide, exclusive license to the University's patent rights relating toits lead drug candidate, Reqorsa \u00ae Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of ALK-EML4 positive translocated lung cancer. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.) \"We continue to bolster our intellectual property portfolio for REQORSA, understanding that our lead drug candidate may benefit patients with many types of cancers,\" said Thomas Gallagher, Esq. , Senior Vice President of Intellectual Property and Licensing at Genprex. \"Positive preclinical data indicate that REQORSA in combination with ALK inhibitors may provide benefit to patients with ALK-positive (ALK+) lung cancer. We are pleased to be able to protect this drug combination for a new subset of lung cancer patients, which widens our exclusivity of drug combinations with REQORSA and enhances our intellectual property position.\" REQORSA in combination with ALK inhibitors could be a potential therapeutic treatment for ALK+ lung cancer. TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer. In fact, approximately 82% of all NSCLCs lack or express decreased amounts of TUSC2 tumor suppressor protein. ALK translocations are found in approximately 5% of NSCLCs. Research collaborators at the University of Michigan Rogel Cancer Center's Judith Tam ALK Lung Cancer Research Initiative presented positive preclinical data at the April 2024 American Association for Cancer Research (AACR) Annual Meeting, reporting that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines . The study found that the use of REQORSA or a TUSC2-containing plasmid to overexpress TUSC2 in ALK+ NSCLC cell lines was effective in decreasing cell growth and proliferation through the activation of apoptotic pathways. Researchers believe the results of this preclinical work support further clinical study of REQORSA as an anti-ALK NSCLC treatment strategy. Genprex believes this research suggests that REQORSA may be an effective treatment in patients progressing on ALK inhibitors. To review the poster presented at the 2024 AACR Annual meeting, visit Genprex's website . Story Continues About Reqorsa \u00ae Gene Therapy REQORSA (quaratusugene ozeplasmid) for NSCLC and small-cell lung cancer (SCLC) consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (Genprex's ONCOPREX \u00ae Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on these current therapies for patients with NSCLC, SCLC, and possibly other cancers. About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex \u00ae Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa \u00ae Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website , registering for Email Alerts and by following Genprex on Twitter , Facebook and LinkedIn . Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under \"Item 1A \u2013 Risk Factors\" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023 . Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment in combination with ALK-inhibitors for ALK-positive lung cancer; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to\u00a0maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations investors@genprex.com GNPX Media Contact Kalyn Dabbs media@genprex.com Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/genprex-signs-exclusive-license-to-additional-gene-therapy-technologies-with-the-university-of-michigan-for-the-treatment-of-lung-cancer-302311506.html SOURCE Genprex, Inc. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2024-11-20T14:29:00+00:00", "sentiment": {"score": 0.7615585476160049, "confidence": 0.7704683542251587, "probabilities": {"positive": 0.7704683542251587, "negative": 0.008909806609153748, "neutral": 0.22062185406684875}}, "embedding": [-0.14243057370185852, 0.07251465320587158, -0.07675843685865402, -0.13389474153518677, -0.055963184684515, -0.020520899444818497, -0.0877278596162796, 0.095695361495018, 0.16422897577285767, -0.014059828594326973, -0.06767897307872772, 0.1246231347322464, 0.08030998706817627, 0.056956566870212555, -0.10761794447898865, 0.24036157131195068, 0.012427114881575108, 0.1140672117471695, -0.11314506083726883, 0.08920849859714508, 0.019371166825294495, 0.0760716050863266, 0.12327796220779419, 0.03766882047057152, 0.010188422165811062, -0.06664737313985825, -0.1130942553281784, 0.08034490048885345, -0.04050953686237335, -0.026992330327630043, 0.14447130262851715, 0.14748117327690125, -0.04293825477361679, -0.09013214707374573, -0.030358828604221344, 0.0899321585893631, -0.13762032985687256, 0.14710867404937744, -0.156603142619133, -0.1125287115573883, 0.08125972747802734, -0.00026962533593177795, -0.08110471069812775, 0.2178688943386078, -0.023335536941885948, -0.16717469692230225, -0.17560353875160217, 0.07959789037704468, -0.0011792555451393127, 0.24900999665260315, -0.047134555876255035, -0.1311691403388977, -0.10136359930038452, 0.21276937425136566, -0.018284134566783905, 0.01592523232102394, -0.18169932067394257, 0.024831080809235573, 0.023259581997990608, 0.0072875251062214375, 0.001527290791273117, -0.09505860507488251, -0.03440949320793152, -0.003634585067629814, 0.11332975327968597, 0.03892219811677933, 0.014668484218418598, -0.11598531901836395, -0.1102934181690216, -0.01128680631518364, 0.07666559517383575, -0.09258018434047699, -0.004357609432190657, 0.3334447741508484, -0.052231382578611374, 0.20354418456554413, 0.1326306015253067, 0.11667127907276154, -0.018196819350123405, -0.11364623159170151, 0.12005482614040375, 0.10645601153373718, 0.06587371975183487, 0.015204777009785175, -0.0023571839556097984, -0.04752618819475174, -0.04810602590441704, 0.06667131185531616, 0.08300843834877014, 0.009510207921266556, -0.01164223998785019, -0.08573174476623535, 0.13350331783294678, -0.012669634073972702, 0.0673895925283432, 0.020350422710180283, -0.052291106432676315, -0.010846655815839767, 0.03332778066396713, -0.0343511700630188, 0.019968168810009956, -0.15249791741371155, -0.04712429642677307, -0.049951694905757904, -0.08176230639219284, -0.0881538987159729, 0.05402551218867302, -0.0458458736538887, -0.016475308686494827, 0.015579390339553356, -0.0316070131957531, 0.061092130839824677, 0.11321929097175598, -0.02514454536139965, -0.030299022793769836, 0.2506725788116455, -0.16605119407176971, -0.02437046729028225, 0.1725795418024063, -0.1683582216501236, -0.149016335606575, -0.0634651631116867, 0.015851695090532303, -0.11271028220653534, 0.14984118938446045, 0.07575371116399765, -0.23110711574554443, 1.0646775596343934e-32, -0.11564825475215912, 0.015463229268789291, 0.0966179370880127, 0.12731489539146423, 0.08639465272426605, -0.12029275298118591, 0.1342507153749466, 0.014516821131110191, -0.2152532935142517, -0.16340577602386475, -0.14125913381576538, 0.10757409036159515, -0.007099244277924299, 0.08542339503765106, 0.052749283611774445, -0.05323927104473114, 0.005102962721139193, -0.002776535227894783, -0.048924047499895096, -0.011792674660682678, -0.0011730892583727837, 0.006212892476469278, -0.05723045393824577, 0.011132754385471344, -0.10497570037841797, -0.029713639989495277, -0.0760568231344223, -0.026711001992225647, 0.12921658158302307, 0.021694958209991455, -0.13041365146636963, 0.16172851622104645, -0.017242591828107834, -0.08673590421676636, 0.015553009696304798, -0.0022713057696819305, -0.11005742847919464, -0.15019837021827698, 0.14196652173995972, 0.10362396389245987, -0.09279852360486984, 0.041859645396471024, -0.11580581963062286, -0.031508609652519226, 0.11240808665752411, -0.1204933449625969, -0.09767068922519684, 0.047441400587558746, -0.04220875725150108, 0.002553134225308895, 0.09548124670982361, -0.011202175170183182, -0.13511478900909424, 0.011672377586364746, -0.13610634207725525, -0.03315126150846481, -0.17061245441436768, 0.042837291955947876, -0.040818650275468826, 0.06973669677972794, -0.13109342753887177, 0.1526096612215042, 0.027451761066913605, 0.09682704508304596, -0.0895846039056778, 0.016859404742717743, -0.06306487321853638, -0.16534295678138733, -0.05698731169104576, 0.15246720612049103, 0.08247561752796173, -0.006479792296886444, 0.10562145709991455, -0.05669050291180611, 0.04594277963042259, -0.14679619669914246, 0.14278104901313782, 0.22609621286392212, 0.0791134387254715, 0.1846739649772644, 0.010806160047650337, 0.07124342024326324, -0.22749698162078857, 0.027165059000253677, -0.12906618416309357, -0.21984350681304932, 0.039824359118938446, -0.03881240263581276, -0.08093869686126709, 0.020740598440170288, 0.1627148985862732, 8.78975261002779e-05, -0.09799228608608246, 0.12363538891077042, 0.016249997541308403, -1.1402777155660026e-32, 0.010787281207740307, -0.03370371460914612, 0.11774146556854248, -0.0300668366253376, -0.05656814202666283, 0.1198606938123703, 0.029903758317232132, -0.1750163435935974, 0.037086665630340576, -0.2036784589290619, 0.13844949007034302, 0.11831669509410858, 0.0779482051730156, -0.009095700457692146, -0.11900003999471664, -0.0784192681312561, -0.03555547446012497, -0.08311605453491211, -0.14403381943702698, -0.05334247648715973, 0.05772056430578232, 0.27542465925216675, -0.06842958927154541, 0.10164292901754379, -0.009480869397521019, -0.09772145003080368, 0.030495766550302505, 0.19149988889694214, 0.03125409781932831, -0.015665050595998764, -0.07444203644990921, 0.11457967758178711, -0.31449034810066223, 0.09262710809707642, 0.052862998098134995, -0.08108417689800262, 0.1255773901939392, -0.11357861757278442, -0.0898132249712944, -0.16217824816703796, 0.10359710454940796, 0.038446951657533646, -0.10202648490667343, 0.06278880685567856, 0.06225108727812767, 0.05778869241476059, 0.03277501463890076, -0.027492571622133255, 0.20116721093654633, -0.06763196736574173, 0.06378453224897385, 0.10041370987892151, 0.01793869212269783, 0.056387320160865784, -0.011667365208268166, 0.03158978745341301, -0.03891869634389877, -0.06478187441825867, -0.08084399253129959, 0.06613074243068695, -0.0017090551555156708, 0.06575600802898407, 0.054429613053798676, -0.040551360696554184, 0.04143039882183075, 0.08064189553260803, 0.08233469724655151, 0.10746688395738602, 0.07340782880783081, -0.043986521661281586, -0.013277671299874783, -0.042665570974349976, -0.06940101832151413, -0.11399836838245392, 0.026320114731788635, 0.132976233959198, 0.1009569764137268, -0.09916792809963226, -0.24408292770385742, -0.11731550097465515, -0.052008721977472305, 0.03354376181960106, 0.03294196352362633, -0.05536753684282303, 0.08645524084568024, 0.13138774037361145, -0.0014984719455242157, 0.018825208768248558, -0.013525382615625858, 0.06447169184684753, -0.05204902961850166, -0.056233134120702744, -0.18494504690170288, 0.07246789336204529, -0.0014153141528367996, -1.0018188589810961e-07, 0.022839505225419998, 0.016146227717399597, 0.019472837448120117, -0.07570035755634308, -0.010033673606812954, 0.009310586377978325, -0.10620883107185364, 0.08192066848278046, -0.04233185946941376, 0.17442238330841064, 0.021126126870512962, 0.17099124193191528, -0.18628525733947754, -0.022471673786640167, -0.05493094399571419, 0.09547331184148788, -0.06784534454345703, 0.007314934395253658, -0.0022765910252928734, -0.023572999984025955, -0.09411969780921936, 0.0048590172082185745, -0.002428574487566948, 0.06591831147670746, -0.08045420050621033, -0.10258082300424576, 0.13932830095291138, -0.0672304555773735, 0.053203437477350235, -0.009038794785737991, -0.06814975291490555, -0.11143429577350616, 0.04542528837919235, 0.07613617181777954, 0.09202957153320312, -0.12840209901332855, 0.07884598523378372, 0.0780378207564354, 0.06992653012275696, 0.13350838422775269, 0.11396792531013489, 0.04183807596564293, 0.009001404978334904, 0.03451205790042877, -0.15131904184818268, -0.08727557212114334, -0.047331418842077255, -0.10650193691253662, -0.010553129017353058, 0.006258058361709118, 0.03355064243078232, -0.02865275740623474, -0.023304644972085953, -0.24142934381961823, -0.0663352683186531, 0.12607859075069427, -0.09686456620693207, -0.0646670013666153, 0.0097726508975029, -0.06917222589254379, 0.11841033399105072, -0.14267271757125854, 0.20339491963386536, 0.07569944858551025], "changes": {"1wk": 1.8181800448205245, "1mo": -18.181822122621057}}, {"text": "PREMIUM Genprex Signs License Deal for University of Michigan's Gene Therapy to Treat Lung Cancer MT Newswires Wed, Nov 20, 2024, 5:45 PM En este art\u00edculo: GNPX -7.84% Genprex Signs License Deal for University of Michigan's Gene Therapy to Treat Lung Cancer PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Mejora \u00bfYa tienes una suscripci\u00f3n? Iniciar sesi\u00f3n Condiciones y Pol\u00edtica de privacidad Privacy Dashboard Historias recomendadas", "symbol": "GNPX", "date": "2024-11-20T14:45:14+00:00", "sentiment": {"score": 0.06316516920924187, "confidence": 0.0791439563035965, "probabilities": {"positive": 0.0791439563035965, "negative": 0.01597878709435463, "neutral": 0.9048771858215332}}, "embedding": [-0.08414114266633987, 0.018994446843862534, 0.05665421485900879, -0.16997075080871582, 0.014425301924347878, -0.02277512475848198, 0.0076915365643799305, 0.13374966382980347, -0.07940401881933212, -0.03540104627609253, 0.04521242529153824, 0.20485340058803558, -0.03183811902999878, 0.03272487595677376, -0.06623078882694244, 0.08286939561367035, 0.007405291311442852, 0.04805195331573486, 0.03464646637439728, 0.03645671531558037, -0.08298754692077637, 0.11684906482696533, 0.1289438158273697, 0.060401998460292816, 0.08275734633207321, 0.06335551291704178, 0.0010396995348855853, 0.02332296408712864, 0.1154671162366867, 0.1397940218448639, 0.11551634967327118, 0.020284460857510567, 0.1211666613817215, -0.04331165552139282, 0.09403064846992493, -0.01597672514617443, -0.01869979128241539, 0.12847211956977844, -0.1709321141242981, -0.03153492137789726, 0.06388869881629944, -0.1058928370475769, -0.07898896187543869, 0.2896682024002075, -0.07493637502193451, -0.11953259259462357, -0.2061462104320526, 0.014924712479114532, 0.04698199778795242, 0.2550414502620697, -0.06904531270265579, -0.23897942900657654, 0.01855868101119995, -0.039102952927351, -0.0381489172577858, -0.06300298124551773, -0.1580507904291153, -0.15301774442195892, -0.05272512882947922, -0.05853736400604248, -0.05026588216423988, -0.12860623002052307, -0.19261446595191956, 0.04185459762811661, 0.04999907687306404, 0.1514912098646164, 0.17895033955574036, -0.07584816962480545, -0.05199025198817253, -0.04690802842378616, 0.11193396896123886, -0.015406670980155468, -0.007864424027502537, 0.21645456552505493, -0.07824204117059708, 0.18277980387210846, 0.15918800234794617, 0.0850386992096901, 0.15627895295619965, -0.13340002298355103, 0.05191585049033165, -0.008077602833509445, 0.11617954820394516, 0.07479619979858398, -0.020910141989588737, 0.0300779789686203, 0.019430942833423615, 0.09535413235425949, 0.12457726150751114, 0.06180739030241966, -0.039129484444856644, 0.015181207098066807, 0.13503508269786835, -0.004426973406225443, -0.15147453546524048, 0.0719049945473671, -0.08017655462026596, -0.09300799667835236, 0.05510461702942848, -0.05175093188881874, -0.06250753998756409, -0.0973002165555954, 0.027912965044379234, 0.03831351920962334, -0.12266916781663895, -0.10146135836839676, -0.06874829530715942, -0.00819648802280426, -0.006058989558368921, 0.10646329075098038, -0.00567166181281209, 0.10666472464799881, 0.061902519315481186, 0.028745276853442192, -0.08399055153131485, 0.25267690420150757, -0.14162275195121765, 0.038557108491659164, 0.2099141627550125, -0.14806945621967316, -0.09819512814283371, -0.08267906308174133, -0.10338767617940903, -0.04469703137874603, 0.0321451872587204, 0.029082663357257843, -0.15742987394332886, 1.7946673391451081e-32, -0.14911706745624542, 0.04162964969873428, 0.08193068206310272, 0.12480515986680984, -0.019904274493455887, 0.03564968332648277, 0.0963602215051651, -0.12345360219478607, -0.2363603413105011, -0.07051773369312286, -0.20111729204654694, 0.14360250532627106, -0.04993414878845215, 0.11696574836969376, -0.08605881780385971, -0.026045558974146843, -0.07931385934352875, 0.07969090342521667, 0.05502010136842728, 0.10695957392454147, 0.029309621080756187, 0.06292014569044113, 0.01334462407976389, -0.03088008239865303, -0.09339962154626846, 0.056183282285928726, -0.08813208341598511, 0.008608497679233551, 0.22796088457107544, 0.03467900678515434, -0.11391609907150269, -0.002666825894266367, 0.03024822473526001, -0.06269120424985886, 0.1117551326751709, 0.08058354258537292, 0.01542473491281271, -0.1666865050792694, 0.06489694118499756, 0.1256093829870224, -0.12506090104579926, 0.026944370940327644, -0.0816931277513504, -0.12375205010175705, 0.07721363753080368, -0.06187719479203224, -0.040844663977622986, -0.1573990136384964, 0.02185354381799698, 0.022043736651539803, -0.05800832808017731, 0.051331885159015656, -0.2428595870733261, -0.03772076219320297, -0.06357310712337494, -0.026678416877985, -0.0845906063914299, 0.07368335872888565, -0.06469037383794785, -0.0854083001613617, 0.028426723554730415, 0.12385411560535431, 0.11833519488573074, -0.015624629333615303, -0.015155966393649578, -0.11719650775194168, -0.10311513394117355, -0.18867461383342743, 0.012908347882330418, 0.16897064447402954, 0.11108497530221939, -0.04332306981086731, -0.028646789491176605, -0.07264325767755508, -0.06623867154121399, -0.0890422835946083, 0.01972620189189911, 0.25910672545433044, 0.06683257222175598, 0.23807115852832794, -0.037068743258714676, -0.013566916808485985, -0.18282698094844818, 0.09077589958906174, 0.1638699471950531, -0.007740823086351156, 0.05544857680797577, 0.07885618507862091, -0.10532770305871964, 0.04305712506175041, 0.1087726503610611, -0.046040866523981094, -0.028543468564748764, 0.12355506420135498, -0.10366414487361908, -2.0027155863716493e-32, -0.09328646212816238, -0.0027073021046817303, 0.12998443841934204, 0.09078014642000198, -0.1034800112247467, 0.028849288821220398, -0.07818131148815155, -0.015991507098078728, 0.09356822073459625, -0.03235393017530441, 0.12781186401844025, 0.08888433873653412, 0.01718566194176674, -0.024429790675640106, -0.0841168686747551, -0.0880146250128746, 0.03575928136706352, -0.115240678191185, -0.2546524703502655, -0.038774650543928146, 0.01606236770749092, 0.21376794576644897, -0.019516747444868088, 0.2354813516139984, -0.10936156660318375, -0.1774911880493164, 0.19847184419631958, 0.21272321045398712, -0.05908484384417534, -0.1180712878704071, -0.09558363258838654, 0.13682326674461365, -0.1958152949810028, 0.09735790640115738, 0.10642435401678085, -0.08589684218168259, 0.2271704077720642, 0.016860894858837128, -0.026625938713550568, -0.14083661139011383, -0.06023898348212242, 0.015841243788599968, -0.15525475144386292, 0.12192194163799286, -0.06966478377580643, 0.10088013857603073, 0.07146554440259933, -0.047447022050619125, 0.13307395577430725, 0.058390501886606216, -0.04103974625468254, 0.07410596311092377, -0.016048476099967957, -0.03830937668681145, -0.08309898525476456, -0.06405593454837799, 0.05661878362298012, -0.05165727809071541, -0.02439209632575512, 0.10842523723840714, 0.1069805920124054, 0.06331997364759445, -0.19388040900230408, -0.09841131418943405, 0.014761097729206085, 0.12966041266918182, 0.032116614282131195, 0.030991345643997192, 0.04577695578336716, 0.0693420022726059, -0.08253808319568634, -0.1633785367012024, -0.10450690239667892, -0.13613571226596832, -0.01593657396733761, 0.0863809809088707, 0.08559182286262512, 0.05599863827228546, -0.051093462854623795, -0.019935354590415955, 0.10700887441635132, -0.09123881906270981, -0.011385831981897354, -0.006967521738260984, 0.06494586914777756, -0.043519578874111176, -0.0009028041386045516, -0.016988590359687805, -0.03961210697889328, 0.0399680957198143, -0.08514831960201263, -0.00137159728910774, -0.17815612256526947, -0.050921663641929626, -0.044108834117650986, -1.008634882282422e-07, 0.01581440679728985, -0.06305832415819168, 0.04593478888273239, -0.057658601552248, -0.044028617441654205, 0.0005544180166907609, -0.13235870003700256, -0.00566847063601017, -0.010960903950035572, 0.20663191378116608, -0.006836396642029285, 0.07108213007450104, -0.212378591299057, -0.027803726494312286, -0.031471241265535355, -0.025195525959134102, -0.08422119915485382, 0.1235242709517479, -0.06495252251625061, -0.09981343895196915, -0.13466309010982513, 0.006435258314013481, 0.01232648640871048, 0.04427504539489746, -0.1322261244058609, -0.05522756651043892, 0.0639018565416336, 0.058465756475925446, 0.07127317786216736, -0.04393280670046806, -0.0971999242901802, -0.05912259966135025, -0.05060712248086929, -0.013684411533176899, -0.03904115408658981, -0.14830069243907928, 0.08834529668092728, 0.013224885798990726, 0.23119008541107178, 0.10740328580141068, 0.11588265001773834, -0.0038506288547068834, 0.013980506919324398, 0.0337471105158329, -0.21785993874073029, 0.08380578458309174, -0.013322531245648861, -0.03325868025422096, -0.0307130366563797, -0.0007053452427498996, 0.09000062942504883, -0.15359218418598175, 0.07118310779333115, -0.14340265095233917, -0.1879873424768448, 0.08337119966745377, 0.007893191650509834, -0.05728403478860855, -0.0203811377286911, 0.005261212587356567, 0.05265657231211662, -0.1456766426563263, 0.07159969210624695, -0.02950691618025303], "changes": {"1wk": -1.8181800448205245, "1mo": -17.27272668160684}}, {"text": "Genprex links with University of Michigan on lung cancer treatment The researchers presented preclinical data \u00b7 Pharmaceutical Technology \u00b7 metamorworks/Shutterstock. GlobalData Thu, Nov 21, 2024, 6:16 PM 2 min read In This Article: GNPX -7.84% Genprex has entered an exclusive licensing agreement with the US University of Michigan for lung cancer therapy, Reqorsa. The company secured global rights to the university's patents related to its Reqorsa gene therapy (quaratusugene ozeplasmid), along with anaplastic lymphoma kinase (ALK)-inhibitors for treating ALK-echinoderm microtubule-associated protein-like 4 (EML4)-positive translocated lung cancer. The University of Michigan Rogel Cancer Center\u2019s Judith Tam ALK [anaplastic lymphoma kinase] lung cancer research initiative researchers have presented encouraging preclinical data, showing that Reqorsa could induce apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines. The study showed that overexpressing tumour suppressor candidate 2 (TUSC2), a gene frequently deleted in lung cancer, using Reqorsa or a TUSC2-containing plasmid, reduced cell growth and proliferation in ALK+ NSCLC cell lines by activating apoptotic pathways. This supports the potential of Reqorsa as a treatment strategy for anti-ALK NSCLC. As Genprex believes, this research suggests that the therapy could be an effective treatment for NSCLC patients who are progressing on ALK inhibitors. Reqorsa, which consists of a TUSC2 gene-expressing plasmid encapsulated in Genprex\u2019s ONCOPREX delivery system, targets cancer cells through their negative electrical charge when injected intravenously. Genprex intellectual property and licensing senior vice-president Thomas Gallagher stated: \u201cWe continue to bolster our intellectual property portfolio for REQORSA, understanding that our lead drug candidate may benefit patients with many types of cancers. \u201cPositive preclinical data indicate that REQORSA in combination with ALK inhibitors may provide benefit to patients with ALK-positive lung cancer. \u201cWe are pleased to be able to protect this drug combination for a new subset of lung cancer patients, which widens our exclusivity of drug combinations with REQORSA and enhances our intellectual property position.\u201d Reqorsa gene therapy is currently undergoing evaluation in two trials for NSCLC and small-cell lung cancer (SCLC). Both lung cancer clinical programmes have received fast track status from the US Food and Drug Administration (FDA), and the SCLC programme has also been granted FDA orphan drug status. The company is also exploring a diabetes gene therapy approach. \"Genprex links with University of Michigan on lung cancer treatment\" was originally created and published by Pharmaceutical Technology , a GlobalData owned brand. Story Continues The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "GNPX", "date": "2024-11-21T15:16:59+00:00", "sentiment": {"score": 0.8674655677750707, "confidence": 0.8746215105056763, "probabilities": {"positive": 0.8746215105056763, "negative": 0.007155942730605602, "neutral": 0.11822246760129929}}, "embedding": [-0.08738468587398529, 0.0459672212600708, -0.10821405053138733, -0.12751683592796326, 0.019995950162410736, -0.12130729854106903, -0.13744017481803894, 0.1145160123705864, 0.17415601015090942, 0.08319942653179169, -0.043308161199092865, 0.06164490059018135, 0.19930021464824677, 0.05216752737760544, -0.11058984696865082, 0.3512343466281891, 0.017175335437059402, 0.1510874330997467, -0.16670912504196167, 0.010392649099230766, 0.02501683495938778, 0.01400840375572443, 0.1488628089427948, 0.040055740624666214, -0.02853868156671524, -0.14539173245429993, -0.12889191508293152, 0.11207658052444458, -0.14751847088336945, -0.09463830292224884, 0.13774898648262024, 0.10987351834774017, -0.05982005596160889, -0.04734749346971512, 0.043228402733802795, 0.10899902135133743, -0.1690332144498825, 0.20728451013565063, -0.15802165865898132, -0.18706819415092468, 0.047483064234256744, -0.003771672025322914, -0.058647520840168, 0.125824972987175, -0.048241026699543, -0.16520297527313232, -0.231001079082489, 0.05594343692064285, 0.04985084384679794, 0.3069332242012024, -0.004339717328548431, -0.06754574179649353, -0.21167348325252533, 0.22282060980796814, -0.03924843296408653, 0.06113092601299286, -0.2481183409690857, 0.1443488895893097, 0.0667075514793396, -0.015292384661734104, 0.04016457870602608, -0.13964951038360596, 0.06772613525390625, 0.01175650954246521, 0.03495664894580841, 0.02349531650543213, -0.03220871090888977, -0.14540401101112366, -0.14968717098236084, 0.09093955159187317, 0.07004834711551666, -0.1263507753610611, 0.026156218722462654, 0.2695992887020111, -0.005699873436242342, 0.1580563187599182, 0.10912374407052994, 0.06308409571647644, -0.1290508508682251, 0.02093392238020897, 0.15131603181362152, 0.11590463668107986, 0.09787244349718094, 0.010346727445721626, 0.042432717978954315, 0.00394027354195714, -0.027641477063298225, -0.021626275032758713, 0.09361162781715393, -0.017279593273997307, 0.05672045052051544, -0.018510980531573296, 0.15562325716018677, -0.02218392863869667, 0.1139252781867981, -0.05338900536298752, 0.015355917625129223, 0.09674258530139923, -0.05979997664690018, -0.06343355029821396, 0.052183642983436584, -0.12936358153820038, -0.05132254213094711, -0.08051855117082596, -0.07448243349790573, -0.15003255009651184, 0.051233917474746704, -0.015358741395175457, -0.07098158448934555, -0.012731105089187622, 0.0183432474732399, -0.013787387870252132, 0.07714297622442245, -0.01267786044627428, 0.004087119363248348, 0.23905688524246216, -0.07610954344272614, -0.11457017064094543, 0.05966900289058685, -0.15055719017982483, -0.06809142231941223, -0.039780162274837494, -0.011876091361045837, -0.052297040820121765, 0.0955318808555603, 0.07979445159435272, -0.1718599498271942, 1.5496656637589421e-32, -0.07576468586921692, -0.01579076424241066, 0.11096787452697754, 0.1451760083436966, 0.08058172464370728, -0.21122270822525024, 0.14461590349674225, 0.015143681317567825, -0.11902892589569092, -0.1377384066581726, -0.16012687981128693, 0.07411839812994003, 0.0718785971403122, 0.034382414072752, -0.011251181364059448, -0.09132024645805359, 0.0071312664076685905, -0.09224221110343933, -0.10107718408107758, -0.02752586640417576, -0.004464469850063324, -0.03233398497104645, -0.07868392020463943, -0.045061249285936356, -0.07475966960191727, -0.013487078249454498, -0.04034130275249481, 0.011569181457161903, 0.1103857010602951, 0.00756700336933136, -0.20115788280963898, 0.19839271903038025, -0.04523659497499466, -0.09772953391075134, -0.00026309629902243614, 0.03353649750351906, -0.06296470016241074, -0.03154491260647774, 0.14126084744930267, 0.08972543478012085, -0.09237955510616302, 0.08211984485387802, -0.17516639828681946, -0.005895742680877447, 0.05975731089711189, -0.16720597445964813, -0.14329177141189575, 0.057533055543899536, -0.04093367978930473, -0.036806050688028336, 0.13558638095855713, -0.11888295412063599, -0.05776781588792801, 0.10093847662210464, -0.10609190165996552, -0.07298728823661804, -0.23273812234401703, -0.02760949358344078, -0.022162074223160744, 0.038637660443782806, -0.12775814533233643, -0.008285455405712128, -0.0014067292213439941, 0.1430225819349289, -0.12198960036039352, -0.0028653405606746674, -0.0586053766310215, -0.14078035950660706, -0.07696651667356491, 0.1599736213684082, 0.060914020985364914, 0.08112367242574692, 0.22181901335716248, -0.0757293850183487, 0.08924144506454468, -0.11643742024898529, 0.2068212479352951, 0.2418510615825653, 0.04817964881658554, 0.30064862966537476, 0.11291992664337158, -0.007993098348379135, -0.21959593892097473, 0.06476844847202301, -0.09733186662197113, -0.3480061888694763, 0.06544152647256851, -0.0019690431654453278, -0.11245889961719513, -0.017343390733003616, 0.25311344861984253, -0.05257174372673035, -0.06084873527288437, 0.17847459018230438, 0.01403120905160904, -1.489731908787917e-32, 0.07827690243721008, 0.0011291508562862873, 0.17359645664691925, -0.010579198598861694, -0.09505730867385864, 0.21842443943023682, 0.09313935041427612, -0.128465473651886, 0.07232889533042908, -0.19429567456245422, 0.12841172516345978, 0.1294548660516739, 0.07406583428382874, 0.023157760500907898, -0.12330915033817291, -0.17246562242507935, -0.05170479416847229, -0.0625237375497818, -0.17556369304656982, 0.06441807001829147, -0.0015742946416139603, 0.17098556458950043, -0.055764202028512955, -0.023456962779164314, -0.06162232905626297, -0.01870638132095337, -0.005363794043660164, 0.12373203039169312, -0.0026219189167022705, 0.014565419405698776, -0.04047483205795288, 0.14238721132278442, -0.22590798139572144, 0.12802377343177795, -0.01328587532043457, -0.07603120058774948, 0.10632999241352081, -0.11879771947860718, -0.09312103688716888, -0.19942063093185425, 0.14908823370933533, 0.054131217300891876, -0.12008833140134811, 0.028665557503700256, 0.03112124651670456, 0.09645774215459824, 0.08837523311376572, 0.04477963596582413, 0.05516663193702698, -0.12799414992332458, -0.0052382987923920155, 0.06616093218326569, -0.09261305630207062, 0.11662730574607849, 0.05275699496269226, 0.1759190410375595, -0.03953804075717926, -0.03106587380170822, -0.08007115125656128, 0.10462373495101929, -0.07181680202484131, 0.03693562000989914, 0.09129127115011215, -0.07339615374803543, 0.031218934804201126, 0.16135354340076447, 0.07352136075496674, 0.13385319709777832, 0.04155345633625984, -0.05125217139720917, -0.0714205950498581, 0.024173161014914513, -0.08369526267051697, -0.06177705526351929, 0.02830733358860016, 0.11868502199649811, 0.02709737792611122, -0.14708879590034485, -0.19372296333312988, -0.08990931510925293, -0.10551551729440689, 0.06553655117750168, -0.02498319186270237, -0.12926733493804932, 0.09517066180706024, 0.1373738944530487, -0.02553194761276245, 0.11019132286310196, -0.06598877161741257, 0.07890959084033966, -0.02505519986152649, -0.1462833285331726, -0.1443764716386795, 0.21772494912147522, 0.08222843706607819, -1.0007612871731908e-07, -0.04652945697307587, 0.05624047666788101, 0.08136849105358124, -0.11699365824460983, -0.05329274758696556, 0.05551772564649582, 0.028118807822465897, 0.12783996760845184, -0.032474055886268616, 0.06381003558635712, 0.03041093982756138, 0.2030896544456482, -0.16087400913238525, -0.09025987982749939, -0.0040668221190571785, 0.1887613832950592, 0.05454012751579285, -0.03602152317762375, 0.03644648194313049, -0.05706533044576645, -0.06435646116733551, -0.07481132447719574, 0.032145027071237564, 0.08172215521335602, -0.07585462927818298, -0.0994444340467453, 0.002725689671933651, 0.10221822559833527, 0.024743331596255302, -0.10498964041471481, -0.13025976717472076, -0.15411989390850067, 0.041728321462869644, -0.028222985565662384, 0.023674413561820984, -0.030849440023303032, 0.08764884620904922, -0.042221251875162125, 0.09657083451747894, 0.14199212193489075, 0.072977215051651, 0.03188510239124298, -0.010685727931559086, -0.008897431194782257, -0.13011738657951355, -0.0559249147772789, -0.0012251646257936954, -0.1453382670879364, -0.048796460032463074, 0.023844826966524124, -0.011366546154022217, -0.066110759973526, -0.0020921232644468546, -0.23460888862609863, -0.11398333311080933, 0.0853423923254013, -0.11023175716400146, -0.045020394027233124, 0.08501757681369781, -0.09218700230121613, 0.07321976125240326, -0.08616964519023895, 0.12297467887401581, 0.11941790580749512], "changes": {"1wk": -5.2631529414422, "1mo": -20.1754352942948}}]